<SEC-DOCUMENT>0001193125-24-160339.txt : 20240613
<SEC-HEADER>0001193125-24-160339.hdr.sgml : 20240613
<ACCEPTANCE-DATETIME>20240613090631
ACCESSION NUMBER:		0001193125-24-160339
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240611
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240613
DATE AS OF CHANGE:		20240613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROKIDNEY CORP.
		CENTRAL INDEX KEY:			0001850270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981586514
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40560
		FILM NUMBER:		241040112

	BUSINESS ADDRESS:	
		STREET 1:		2000 FRONTIS PLAZA BLVD.
		STREET 2:		SUITE 250
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103
		BUSINESS PHONE:		336-999-7028

	MAIL ADDRESS:	
		STREET 1:		2000 FRONTIS PLAZA BLVD.
		STREET 2:		SUITE 250
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Social Capital Suvretta Holdings Corp. III
		DATE OF NAME CHANGE:	20210310
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d814183d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prok="http://www.prokidney.com/20240611" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2024-06-11_to_2024-06-11" name="dei:AmendmentFlag" contextRef="duration_2024-06-11_to_2024-06-11">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2024-06-11_to_2024-06-11" name="dei:EntityCentralIndexKey" contextRef="duration_2024-06-11_to_2024-06-11">0001850270</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="prok-20240611.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-06-11_to_2024-06-11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-11</xbrli:startDate> <xbrli:endDate>2024-06-11</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_1">8-K</ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt:date-monthname-day-year-en" id="Fact_0">June&#160;11, 2024</ix:nonNumeric></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_2">PROKIDNEY CORP.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:edgarprovcountryen" id="Fact_3">Cayman Islands</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_4">001-40560</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_5">98-1586514</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_6">2000 Frontis Plaza Blvd.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_7">Suite 250</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_8">Winston-Salem</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:stateprovnameen" id="Fact_9">North Carolina</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_10">27103</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_11">336</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_12">999-7019</ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:boolballotbox" id="Fact_14">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:boolballotbox" id="Fact_20">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:boolballotbox" id="Fact_22">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:boolballotbox" id="Fact_24">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_25">Class&#160;A ordinary shares, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_26">PROK</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:exchnameen" id="Fact_27">The Nasdaq Stock Market</ix:nonNumeric></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:boolballotbox" id="Fact_16">&#9746;</ix:nonNumeric></p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-06-11_to_2024-06-11" format="ixt-sec:boolballotbox" id="Fact_18">&#9744;</ix:nonNumeric></p><p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Underwriting Agreement</p><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, ProKidney Corp. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), relating to the public offering of 42,744,220 shares of the Company&#8217;s Class&#160;A ordinary shares, $0.0001 par value per share (the &#8220;Ordinary Shares&#8221;), at an offering price to the public of $2.42 per share (the &#8220;Public Offering&#8221;). Under the terms of the Underwriting Agreement, the Company granted the Underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to an additional 6,411,633 Ordinary Shares. The Public Offering is expected to close on June&#160;13, 2024, subject to the satisfaction of customary closing conditions.</p><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purchase Agreement</p><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the Public Offering, on June&#160;11, 2024, the Company entered into share purchase agreements (the &#8220;Purchase Agreements&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Investors agreed to purchase 11,030,574 Ordinary Shares, $0.0001 par value per share, in a registered direct offering (the &#8220;Direct Offering&#8221;). The Public Offering is not contingent on the closing of the Direct Offering, and the Direct Offering is not contingent on the closing of the Public Offering. The Direct Offering is expected to close on or about June&#160;13, 2024.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreements can be terminated (i)&#160;by mutual agreement of the Company and each Investor, or (ii)&#160;by either party if the Direct Offering does not close by June&#160;17, 2024. The Purchase Agreements contain customary representations and warranties. The obligation of the Investors to purchase our shares is also subject to certain conditions precedent in the Purchase Agreements.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to the Company from the Public Offering and the Direct Offering are expected to be approximately $136.7&#160;million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Public Offering and the Direct Offering were made pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-275701),</span> that was filed with the Securities and Exchange Commission and became effective on November&#160;30, 2023, including the related prospectus, dated November&#160;30, 2023, as supplemented by the preliminary prospectus supplement dated June&#160;10, 2024 and the final prospectus supplement dated June 11, 2024. The description of the material terms of the Underwriting Agreement and the Purchase Agreements in Items 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> do not purport to be complete and are qualified in their entirety by reference to the terms of the Underwriting Agreement and the Purchase Agreements, as applicable. Copies of the Underwriting Agreement and a Form of the Purchase are attached as Exhibits 1.1 and 10.1, respectively, and incorporated herein by reference. A copy of the legal opinion relating to the legality of the issuance and sale of common stock in the Public Offering and the Direct Offering is attached hereto as Exhibit 5.1.</p><p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 11, 2024, the Company issued a press release announcing the pricing of the Public Offering. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814183dex11.htm">Underwriting Agreement by and between the Company and Jefferies LLC, J.P. Morgan Securities LLC, and Guggenheim Securities, LLC, dated June&#160;11, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814183dex51.htm">Opinion of Walkers (Cayman) LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814183dex101.htm">Form of Share Purchase Agreement by and between the Company and certain investors, dated June&#160;11, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814183dex51.htm">Consent of Walkers (Cayman) LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814183dex991.htm">Press Release dated June 11, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr></table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top">*</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation <span style="white-space:nowrap">S-K.</span></p></td></tr></table></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:45%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>
<td style="vertical-align:bottom"/>
<td style="width:3%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">PROKIDNEY CORP.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;13, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Coulston</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">James Coulston</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d814183dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>42,744,220 Class&nbsp;A Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ProKidney Corp. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">June&nbsp;11, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GUGGENHEIM SECURITIES, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o JEFFERIES
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. MORGAN SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Guggenheim Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">330 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B>
ProKidney Corp., a Cayman Islands exempted company (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of 42,744,220 of its
Class&nbsp;A Ordinary Shares, par value $0.0001 per share (the &#147;<B>Shares</B>&#148;). The 42,744,220 Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has granted to the Underwriters an
option to purchase up to an additional 6,411,633 Shares, as provided in Section&nbsp;2. The additional 6,411,633 Shares to be sold by the Company pursuant to such option are collectively called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares
and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; Jefferies LLC (&#147;<B>Jefferies</B>&#148;), J.P. Morgan Securities LLC (&#147;<B>J.P. Morgan</B>&#148;) and
Guggenheim Securities, LLC (&#147;<B>Guggenheim</B>&#148;) have agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares.
To the extent there are no additional underwriters listed on <U>Schedule A</U>, the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural,
as the context requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) a shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275701,</FONT> including a base prospectus (the &#147;<B>Base
Prospectus</B>&#148;) to be used in connection with the public offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became
effective under the Securities Act of 1933, as amended, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or deemed to be incorporated by reference therein
and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the Company pursuant to Rule
462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of any such Rule 462(b) Registration
Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement dated June&nbsp;10, 2024 describing the Offered Shares and the offering thereof (the
&#147;<B>Preliminary Prospectus Supplement</B>&#148;), together with the Base Prospectus, is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other prospectus supplement to the Base Prospectus in
preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#147;<B>preliminary prospectus</B>.&#148; As used
herein, the term &#147;<B>Prospectus</B>&#148; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Shares and the offering thereof (the &#147;<B>Final Prospectus Supplement</B>&#148;), together with the Base
Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act.
References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such prospectus. As used herein, &#147;<B>Applicable Time</B>&#148; is
9:00 p.m. (New York City time) on June 11, 2024. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary
Prospectus, as amended or supplemented immediately prior to the Applicable Time. As used herein, &#147;<B>Road Show</B>&#148; means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered
Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). As used herein, &#147;<B>Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on
Section&nbsp;5(d) or Rule 163B of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&#147;<B>QIBs</B>&#148;) and/or institutions
that are accredited investors (&#147;<B>IAIs</B>&#148;), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Shares;
&#147;<B>Oral <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means each oral communication, if any, made in reliance on Section&nbsp;5(d) or Rule 163B of the Securities Act
by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<B>Marketing
Materials</B>&#148; means any materials or information provided, presented or transmitted simultaneously to investors by the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor
presentations made to investors by the Company (whether in person or electronically); and &#147;<B>Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means the Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication(s) and Marketing Materials listed on Schedule B attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, on June&nbsp;11, 2024, the Company entered into a
stock purchase agreement (any transactions contemplated thereby, the &#147;<B>Registered Direct Offering</B>&#148;)<B> </B>pursuant to which certain investors have agreed to purchase $26,558,989.38 worth of shares of Shares (the &#147;<B>Registered
Direct Shares</B>&#148;) at the price to the public set forth in the Time of Sale Prospectus. The closing of the Registered Direct Offering is not contingent upon the closing of the offering contemplated by this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this underwriting agreement (the &#147;<B>Agreement</B>&#148;) to the
Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to
financial statements and schedules and other information which are &#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary
Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other
information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus
shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;) that is or is deemed to be
incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to (i)&nbsp;the Registration Statement, the
Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the Prospectus, or any amendments or supplements to any of the foregoing, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval System (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; (as defined below) provided for use in connection with the offering of the Offered Shares as
contemplated by Section&nbsp;3(n) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreements with the Underwriters as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B>Representations and Warranties</B><B> of the Company.</B><B> </B>The Company hereby represents,
warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Compliance with Registration Requirements</I></B><B>.</B> The Registration Statement has become effective under the Securities
Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and
no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. At the time the Company&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 (the &#147;<B>Annual Report</B>&#148;) was filed with the Commission, or, if later, at the time the Registration Statement was originally filed with the
Commission, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Securities Act specified in Financial Industry Regulatory Authority, Inc.&#146;s (&#147;<B>FINRA</B>&#148;) Conduct Rule 5110(h)(1)(C). The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time
of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the
Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Disclosure</I></B><B>.</B> Each preliminary prospectus and the Prospectus when filed complied in all
material respects with the Securities Act and, if filed with the Commission through EDGAR (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act), was identical to the copy thereof
delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in
all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of
the Applicable Time, the Time of Sale </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus did not, and at the First Closing Date (as defined in Section&nbsp;2), and at each applicable Option Closing Date (as defined in Section&nbsp;2), will not, contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus, as of its date did not, and at the First Closing Date and at
each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time
of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being
understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed
as exhibits to the Registration Statement which have not been described or filed as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Free Writing
Prospectuses</I></B><B>.</B> The Company is an &#147;ineligible issuer&#148; as defined in Rule 405 of the Securities Act. The Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any
free writing prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Distribution of Offering Material by the Company</I></B><B>.</B> Prior to the later of
(i)&nbsp;the expiration or termination of the option granted to the several Underwriters in Section&nbsp;2, and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares, the Company has not distributed and will not
distribute any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus and any Permitted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Form
<FONT STYLE="white-space:nowrap">S-3.</FONT></I></B> The Company and the transactions contemplated by this Agreement meet the requirements for, and comply with the conditions for the use of, Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the
Securities Act, including the transaction requirements set forth in General Instruction I.B.1 of such form. The Company is subject to and in compliance in all material respects with the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d)
of the Exchange Act. The Company is not a shell company (as defined in Rule 405 of the Securities Act) and has not been a shell company for at least twelve (12)&nbsp;calendar months previously and if it has been a shell company at any time
previously, has filed current Form 10 information (as defined in Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3)</FONT> with the Commission at least twelve (12)&nbsp;calendar months previously reflecting its status as an entity that
is not a shell company. The Registration Statement meets the requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with said Rule, and the Prospectus Supplement will meet the requirements set forth in Rule 424(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Incorporated Documents</I></B>. The documents incorporated or deemed to be incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other
information in the Prospectus, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Exchange Act Compliance</I></B>. The documents incorporated or deemed to be incorporated by
reference in the Registration Statement, Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act, and,
when read together with the other information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at the First Closing Date and each Option Closing Date, as the case may be, will not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Statistical and Market-Related Data</I></B>. All statistical, demographic
and <FONT STYLE="white-space:nowrap">market-related</FONT> data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be
reliable and accurate. To the extent required, the Company has obtained the written consent for the use of such data from such sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</I></B>. The
Company has established and maintains disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others within those entities, particularly
during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and
(iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in
the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the
Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>The Underwriting
Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Authorization
of the </I></B><B><I>Offered Shares</I></B><B>.</B> The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement and
the register of members of the Company has been updated by the transfer agent of the Company to reflect the issuance of the Offered Shares (by entry of the name of the registered owner thereof confirming that such Offered Shares have been issued and
credited as fully paid), will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the
Offered Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>No Applicable Registration or Other Similar Rights</I></B><B>.</B> There are no persons with
registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived or satisfied
prior to the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>No Material Adverse Change</I></B><B>.</B> Since the date of the most recent financial
statements of the Company included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that would reasonably be expected
to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the
ordinary course of business, of the Company and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such
change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii)&nbsp;the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including
without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or
decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any
material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or,
except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock (other
than redemption or exchange of common units of ProKidney LP (&#147;PKLP&#148;) for the Company&#146;s Class&nbsp;A Ordinary Shares as the Company may complete from time to time pursuant to the second amended and restated limited partnership
agreement of PKLP and the exchange agreement, dated as of July&nbsp;11, 2022, by and among the Company, PKLP and certain PKLP unitholders). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Independent Accountants</I></B><B>.</B> Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the
financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an independent registered
public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the applicable requirements relating to the qualification
of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration
has not been suspended or revoked and who has not requested such registration to be withdrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Financial
Statements</I></B><B>.</B> The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly, in all material respects, the consolidated financial position of
the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally
accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto and except in the case of unaudited financial statements,
which are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain all footnotes as permitted by the applicable rules of the Commission. The interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto.
No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. The financial data set forth in each of the Registration Statement, the Time of Sale
Prospectus and the Prospectus fairly present the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus.<B> </B>To the
Company&#146;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or
otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Company</I></B><B><I>&#146;</I></B><B><I>s Accounting
System</I></B><B>.</B> The Company and each of its subsidiaries make and keep books and records that are accurate in all material respects and maintain a system of internal accounting controls sufficient to provide reasonable assurance that:
(i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Incorporation and Good Standing of the Company</I></B><B>.</B> The Company has been duly incorporated and is
validly existing as a Cayman Islands exempted company in good standing (where such concept is recognized) under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and
to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact
business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing, as
the case may be, would not result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>Subsidiaries</I></B><B>.</B> Each of the Company&#146;s
&#147;subsidiaries&#148; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability
company, as applicable, in good standing (where such concept is recognized) under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to
conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as
applicable, to transact business and is in good standing (where such concept is recognized) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except
where the failure to be so qualified or in good standing, as the case may be, would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s
subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned (or, in the case of any partly-owed subsidiaries, to the extent owned) by the Company, directly or through subsidiaries, free and clear of any
security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary.
The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does
not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal
year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Capitalization and Other Capital Stock Matters</I></B><B>.</B> The authorized, issued
and outstanding capital stock of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Description of Shares&#148; (other than for subsequent issuances, if any, pursuant to
employee benefit plans described in the Prospectus, or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus). The Shares (including the Offered Shares) conform in all material respects to the description thereof contained in the Time of Sale Prospectus and the Prospectus. All of the issued
and outstanding Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all applicable federal and state securities laws. None of the outstanding Shares was issued in violation of
any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to
purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. The descriptions of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the
Prospectus accurately and fairly presents, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Stock Exchange Listing</I></B><B>.</B> The Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act
and are listed on the Nasdaq Capital Market (the &#147;<B>Nasdaq</B>&#148;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares
from the Nasdaq, nor has the Company received any notification that the Commission or the Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance with all applicable listing requirements
of the Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further
Authorizations or Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar
organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract,
franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its
subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as would not be expected,
individually or in the aggregate, to result in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of
Sale Prospectus and the Prospectus and the issuance and sale of the Offered Shares (including the use of proceeds from the sale of the Offered Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under
the caption &#147;Use of Proceeds&#148;) (i)&nbsp;have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership
agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary (ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below)
under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except as
would not be expected to result in a Material Adverse Change and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No consent,
approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and consummation
of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as
may be required under applicable state securities laws, the laws of the Cayman Islands, or blue sky laws or FINRA. As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition which gives, or with the giving of
notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or any of its subsidiaries. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>No Material Actions or Proceedings</I></B><B>.</B> There is no action,
suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would be expected,
individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company or any of its subsidiaries, or, to the knowledge of the Company, with the employees of any principal supplier,
manufacturer, customer or contractor of the Company, exists or is threatened or imminent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w) </B><B><I>Intellectual Property
Rights</I></B><B>.</B><B></B>&nbsp;Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change, the Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the
inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or
licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#147;<B><I>Intellectual Property</I></B>&#148;) and, to the Company&#146;s
knowledge, the conduct of their respective businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The material Intellectual Property of the Company has not been
adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company&#146;s knowledge: (i)&nbsp;there
are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus
and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property, except, in the case of any of clauses (i)&nbsp;or (ii) above, for any such rights
held by third parties or infringement by third parties as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. There is no pending or threatened in writing action, suit, proceeding or claim by
others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity,
enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries
infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any patent, trademark,
trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim, except, in the case of any of
clauses (A)-(C) above, for any such pending or threatened action, suit, proceeding or claim as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change. The Company and its subsidiaries have complied with
the terms of each material agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary in all material respects, and all such agreements are in full force and effect. To the Company&#146;s knowledge, there
are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken commercially reasonable steps to protect, maintain and safeguard their material Intellectual
Property, including the execution of nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#146;s knowledge, no employee of the Company is in or has been in
violation of any term of any patent disclosure agreement or invention assignment agreement to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company in any material respect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x) </B><B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and each subsidiary
possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement,
the Time of Sale Prospectus or the Prospectus (&#147;<B>Permits</B>&#148;), except where the failure to or possess or obtain the same would not reasonably be expected to result in Material Adverse Change. Neither the Company nor any of its
subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such certificate,
authorization or permit, except for such violation, defaults or proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any such Permits, that would not reasonably be expected to
result in Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y) </B><B><I>Title to Properties</I></B><B>.</B> The Company and its subsidiaries have good and
marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(o) above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the
Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects. The real property, improvements, equipment and personal property held under lease by the Company or any
of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by
the Company or such subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z) </B><B><I>Tax Law Compliance</I></B><B>.</B> Except as would not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Change, (i)&nbsp;the Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns required to be filed by them or have properly
requested extensions thereof and have paid all material taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith
and by appropriate proceedings, and (ii)&nbsp;the Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;1(o) above in respect of all federal, state and foreign income and
franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa) </B><B><I>Company Not an </I></B><B><I>&#147;</I></B><B><I>Investment Company.</I></B><B><I>&#148;</I></B> The Company is not, and
will not be, either after receipt of payment for the Offered Shares and the Registered Direct Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale
Prospectus or the Prospectus, required to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the <B>&#147;</B><B>Investment Company Act</B><B>&#148;</B><B>)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb) </B><B><I>Insurance</I></B><B>.</B> Each of the Company and its subsidiaries are insured by recognized, financially sound and
reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property
owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The
Company has no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be
necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage
which it has sought or for which it has applied. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc) </B><B><I>No Price Stabilization or Manipulation; Compliance with Regulation
M</I></B>. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or of any &#147;reference security&#148;
(as defined in Rule 100 of Regulation M under the Exchange Act (<B>&#147;</B><B>Regulation M</B><B>&#148;</B>)) with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and has taken no action which
would directly or indirectly violate Regulation M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd) </B><B><I>Related Party Transactions</I></B>. There are no business
relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus which have not been described as
required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee) </B><B><I>FINRA Matters</I></B><B>.</B> All of the information provided to the Underwriters or to counsel for the
Underwriters by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Shares is true, complete,
correct and compliant with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff) </B><B><I>No Unlawful Contributions or Other Payments</I></B>. Neither the Company nor any of its subsidiaries nor, to the best of the
Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character
required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg) </B><B><I>Compliance with
Environmental Laws</I></B><B>.</B> Except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state,
local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to
pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under
any applicable Environmental Laws and are each in compliance with their requirements; (iii)&nbsp;there are no pending administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings, and to the Company&#146;s knowledge, no such matters have been threatened in writing, relating to any Environmental Law against the Company or any of its subsidiaries; and (iv)&nbsp;there are no events or
circumstances that might reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or
affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>hh</B><B>)
</B><B><I>Periodic Review of Costs of Environmental Compliance</I></B><B>.</B> In the ordinary course of its business, the Company conducts a periodic review of the effect of Environmental Laws on the business, operations and properties of the
Company and its subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT>
closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties). No facts or circumstances have come to the
Company&#146;s attention that could result in costs or liabilities that could be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>ERISA Compliance</I></B><B>.</B> The Company and its subsidiaries and any
&#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by
the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company or any of its subsidiaries, any
member of any group of organizations described in Sections&nbsp;414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the
Company or such subsidiary is a member. No &#147;reportable event&#148; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its
subsidiaries or any of their ERISA Affiliates. No &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have
any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i)&nbsp;Title&nbsp;IV of ERISA
with respect to termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (ii)&nbsp;Sections&nbsp;412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any
of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>jj</B><B>) </B><B><I>Brokers</I></B><B>.</B> Except as otherwise disclosed in the Prospectus, there is no broker, finder or other
party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk) </B><B><I>No Outstanding Loans or Other Extensions of Credit</I></B>. The Company does not have any outstanding extension of credit,
in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll) </B><B><I>Compliance with Laws.</I></B> The Company and its subsidiaries have been and are in compliance with all applicable laws,
rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm) </B><B><I>Dividend Restrictions</I></B><B>.</B> No subsidiary of the Company is prohibited or restricted, directly or indirectly, from
paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due
under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn) </B><B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> The Company has furnished to the
Underwriters a letter agreement in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;A</U> (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from each of the persons listed on
<U>Exhibit</U><U></U><U>&nbsp;B</U>. Such <U>Exhibit</U><U></U><U>&nbsp;B</U> lists under an appropriate caption the directors, executive officers and certain shareholders of the Company. If any additional persons shall become directors or executive
officers of the Company prior to the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a
director or executive officer of the Company, to execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo) </B><B><I>Anti-Corruption and Anti-Bribery Laws</I></B><B>.</B> Neither the Company
nor any of its subsidiaries nor any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has,
in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made
or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public
international organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
&#147;<B>FCPA</B>&#148;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment or benefit . The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B><B><I>Money Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are, and have been conducted at all
times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq) </B><B><I>Clinical Data and Regulatory Compliance.</I></B> The preclinical tests and clinical trials, and other studies (collectively,
&#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all respects in accordance with the
protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all respects and fairly presents the
data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration
Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human
Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or Institutional Review Board (collectively, the &#147;<B>Regulatory Agencies</B>&#148;); neither the Company nor any of its
subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale
Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all respects with all applicable rules, regulations and policies of the Regulatory Agencies; except in each case as would not
reasonably be expected to result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr) </B><B><I>Sanctions</I></B><B>.</B> Neither the Company nor any of
its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of
any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury of the United Kingdom (including as extended to the
Cayman Islands by Order in Council), and the Cayman Islands, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory
that is the subject or the target of Sanctions, including, without limitation, the Crimea Region and the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine (or any other Covered
Region of Ukraine identified pursuant to Executive Order 14065), the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba, Iran,
North Korea and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for
the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any
person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past ten years, the Company and its subsidiaries have not knowingly engaged in and are not now
knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss) </B><B><I>Sarbanes-Oxley</I></B>. The Company is in compliance, in all material respects, with all applicable provisions of the
Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt) </B><B><I>Forward-Looking Statements.</I></B>
Each financial or operational projection or other &#147;forward-looking statement&#148; (as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale
Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and
(ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement. No such statement was
made with the knowledge of an executive officer or director of the Company that it was false or misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu) </B><B><I>Duties,
Transfer Taxes, Etc</I></B>. No stamp or other issuance or transfer taxes or duties are payable in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of
this Agreement by the Company or the sale and delivery by the Company of the Offered Shares, except as may be fully refundable on the same day as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv) </B><B><I>Choice of Law</I></B>. Under the laws of the Cayman Islands and as set out in the Time of Sale Prospectus and the
Prospectus, the courts of the Cayman Islands will recognize and give effect to the governing law provisions set forth in Section&nbsp;19 hereof and enforce judgments of U.S. courts obtained against the Company, the governing law provisions set forth
in Section&nbsp;19 hereof will be recognized by the courts of the Cayman Islands and any judgment obtained in any state or federal court located in the Borough of Manhattan, The City of New York, New York arising out of or in relation to the
obligations of the Company under this Agreement will be recognized in Cayman Islands courts relating to the enforceability of foreign judgments and the statements set forth in the Prospectus under the caption &#147;Enforcement of Civil
Liabilities&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww) </B><B><I>Cybersecurity</I></B>. (i)&nbsp;The Company and its subsidiaries&#146; information technology assets
and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all material respects as required in connection with,
the operation of the business of the Company and its subsidiaries as currently </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants and (ii)&nbsp;the Company and its subsidiaries have implemented and
maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and
security of all IT Systems and material data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (A)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number; (B)&nbsp;any
information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (C) &#147;personal data&#148; as defined by the GDPR; (D)&nbsp;any information which would qualify as
&#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA&#148;</B>); and
(E)&nbsp;any other piece of information that reasonably allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation.
There have been no material breaches, violations, outages or unauthorized uses of or accesses to the IT Systems, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents
under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
misappropriation or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx) </B><B><I>Compliance with Data Privacy Laws</I></B>. Except as would not be expected,
individually or in the aggregate, to result in a Material Adverse Change, (i)&nbsp;the Company and its subsidiaries are in compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation
HIPAA, and the Company and its subsidiaries currently are in compliance with the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;), (ii) the Company and its
subsidiaries have in place, comply with, and take appropriate steps reasonably designed to comply in all respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and
analysis of Personal Data (the &#147;<B>Policies</B>&#148;), (iii) the Company and its subsidiaries have made disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or
contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any respect and (iv)&nbsp;neither it nor any subsidiary: (A)&nbsp;has received written
notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would result in any such notice; (B)&nbsp;is currently conducting or
paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (C)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy) </B><B><I>Emerging Growth Company Status.</I></B> From the time of the initial filing of the Registration Statement with the
Commission (or, if earlier, the first date on which the Company engaged in any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any Oral <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging
Growth Company</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz) </B><B><I>Compliance with Health Care Laws</I></B>. The Company and its subsidiaries are, and at all
times have been, in material compliance with all applicable Health Care Laws. For purposes of this Agreement, &#147;Health Care Laws&#148; means, as applicable to the Company and its subsidiaries: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation,
the Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C.
Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare
programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and
Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational
and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart
thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or
other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care
Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent
submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory
authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human
clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa) </B><B><I>Communications.</I></B> The Company (i)&nbsp;has not alone engaged in communications with potential investors in reliance
on Section&nbsp;5(d) or Rule 163B of the Securities Act other than Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives with entities that
are, or are reasonably expected to be, QIBs or IAIs and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in
undertaking Marketing Materials, Oral <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications; as of the Applicable Time, each Permitted
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb) </B><B><I>No Rights to Purchase Shares</I></B>. The issuance and sale of the Offered Shares as contemplated hereby will not cause any
holder of any Shares, securities convertible into or exchangeable or exercisable for Shares or options, warrants or other rights to purchase Shares or any other securities of the Company to have any right to acquire any Shares of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc) </B><B><I>No Contract Terminations</I></B>.<B><I></I></B>&nbsp;Neither the Company
nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in the Registration Statement, the Time of Sale Prospectus or the
Prospectus, and no such termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has been threatened by the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any other party to any such contract or agreement, which
threat of termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has not been rescinded as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a
representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for
making each of the representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the
Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B>Purchase, Sale and Delivery of the </B><B>Offered Shares</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>The </I></B><B><I>Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the
several Underwriters an aggregate of 42,744,220 Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and
not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule</U><B><U> </U></B><U>A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be
$2.2748 per share; provided that an aggregate of 26,740,139 of the 30,882,371 Firm Shares proposed to be sold by the Underwriters to entities affiliated with the Company&#146;s 5% shareholders and directors shall be purchased at $2.42 per Firm
Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the Firm Shares to be purchased by the
Underwriters and payment therefor shall be made at the offices of Paul Hastings LLP, The MetLife Building, 200 Park Avenue, New York, New York 10166 (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New
York City time, on June&nbsp;13, 2024<B>,</B> or such other time and date not later than 1:30&nbsp;p.m. New York City time, on June&nbsp;28, 2024 as the Representatives shall designate by notice to the Company (the time and date of such closing are
called the &#147;<B>First Closing Date</B>&#148;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any
determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 6,411,633 Optional Shares
from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on Optional
Shares; provided that, the first 4,142,232 Optional Shares purchased from the Company shall be purchased at a purchase price of $2.42 per Optional Share. The option granted hereunder may be exercised at any time and from time to time in whole or in
part upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the
Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which certificates for the Optional Shares will be </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the
term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of certificates for the Firm Shares and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an
&#147;<B>Option Closing Date</B>,&#148; and shall be determined by the Representatives and shall not be earlier than one or later than two full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, each
Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional
Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares. The Representatives may cancel the option at any time prior to its expiration by
giving written notice of such cancellation to the Company.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Public Offering of the </I></B><B><I>Offered
Shares</I></B><B>.</B> The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their
respective portions of the Offered Shares as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Payment for the </I></B><B><I>Offered Shares</I></B><B>.</B> (i)&nbsp;Payment for the Offered Shares to be sold by the
Company shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives have been authorized, for their own account and the accounts of the several
Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies, J.P. Morgan and Guggenheim, individually and not as
the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the
applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Delivery of the </I></B><B><I>Offered Shares</I></B><B>.</B> The Company shall deliver, or cause to be delivered to the
Representatives for the accounts of the several Underwriters certificates for the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company
shall also deliver, or cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option
Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the Offered Shares may be made by credit to the
accounts designated by the Representatives through The Depository Trust Company&#146;s full fast transfer or DWAC programs. If the Representatives so elect, the certificates for the Offered Shares shall be registered in such names and denominations
as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the
First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a
further condition to the obligations of the Underwriters. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. </B><B>Additional Covenants</B><B> of the
Company</B><B>.</B><B> </B>The Company further covenants and agrees with each Underwriter as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Delivery of
Registration Statement, Time of Sale Prospectus and Prospectus</I></B><B><I>.</I></B><I> </I>The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of
this Agreement and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in
connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed Amendments and Supplements</I></B><B><I>.</I></B><I>
</I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will
furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not
amend or supplement the Registration Statement without the Representatives&#146; prior written consent. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, the Company shall furnish to the
Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment
or supplement without the Representatives&#146; prior written consent. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such
Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>[Reserved]</I></B><B></B><B><I>.</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The Company shall not take any action that would result in an
Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Amendments and Supplements to Time of Sale Prospectus</I></B><B><I>.</I></B><I> </I>If the Time of Sale Prospectus is being
used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a
prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of counsel for the
Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and Section&nbsp;3(c) hereof) promptly prepare, file with the Commission and furnish, at
its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as
amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date
of this Agreement, the Company shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date of any filing
of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective amendment to the
Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any
preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, or of any proceedings to remove, suspend or
terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the
Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with all applicable provisions
of Rule&nbsp;424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Amendments and Supplements to the Prospectus and Other Securities Act Matters</I></B><B><I>.</I></B> If any event shall occur
or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the
Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b) and Section&nbsp;3(c)) hereof to promptly prepare, file
with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the
Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#146; consent to, nor delivery of, any such amendment or
supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or Section&nbsp;3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)
</B><B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state
securities or blue sky laws of those jurisdictions designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered
Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified. The Company will advise the
Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such
purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>) </B><B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the
net proceeds from the sale of the Offered Shares sold by it in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its security holders and to the
Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy
the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)
</B><B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>,
</B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act
to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and the Nasdaq all reports and documents required to be filed under the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Listing</I></B><B>.</B> The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares
on the Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Company to Provide Copy of the Prospectus in Form That May </I></B><B><I>be</I></B><B><I> Downloaded from
the Internet</I></B><B>.</B> If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<B>electronic
Prospectus</B>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Prospectus, and any amendment or supplement
thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and
purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material
shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format,
satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and
for <FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it
was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the period commencing on and including the date
hereof and continuing through and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT>
</B><B>Period</B>&#148;), the Company will not, without the prior written consent of Jefferies and J.P. Morgan (which consent may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend
any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase any &#147;put equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call equivalent
position&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)</FONT> under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities;
(iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related
Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;submit or file any registration statement under the
Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar
transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby (including the Registered
Direct Offering), (B) issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, but only if the holders of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period without the prior written consent of Jefferies and J.P. Morgan (which consent may be withheld in their sole discretion), and (C)&nbsp;sell Shares pursuant to the Open Market Sales Agreement<SUP
STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated January&nbsp;19, 2024, by and between the Company and Jefferies (the &#147;<B>ATM Agreement</B>&#148;); <I>provided</I>, <I>however</I>, no sales shall be made pursuant to the ATM Agreement
until 30 days following the date of the Prospectus. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or
convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Future Reports to the Representative</I></B><B><I>s</I></B><B><I>.</I></B><I> </I>During the period of five years hereafter,
the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate; c/o J.P. Morgan, at 383 Madison Avenue, New York, New York 10179, fax: (212) <FONT
STYLE="white-space:nowrap">622-8358,</FONT> Attention: Equity Syndicate Desk; and c/o Guggenheim, at 330 Madison Avenue, New York New York, Attention: Head of Equity Capital Markets: (i)&nbsp;as soon as practicable after the end of each fiscal year,
copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146;<I> </I>equity and cash flows for the year then ended and the opinion thereon of
the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on
Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available,
copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this Section&nbsp;3(p) shall be satisfied to the extent that such reports,
statement, communications, financial statements or other documents are available on EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Investment
Limitation</I></B><B>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment
company under the Investment Company Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>No Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation
M</I></B><B>.</B> The Company will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any
reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement</I></B><B><I>s</I></B><B>.</B> During the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in
operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will
direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such
agreements, including, without limitation, <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers and directors pursuant to Section&nbsp;6(i) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each applicable Option
Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by
the most recent financial statements appearing in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Amendments and
Supplements to Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. </I></B><I></I>If at any time following the distribution of any Permitted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, there occurred or occurs an event or development as a result of which such Permitted
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>Emerging Growth Company Status.</I></B> The Company will promptly notify the Representatives if the Company ceases to be an
Emerging Growth Company at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Shares is not required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the
Securities Act or any similar rule) and (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of
any one or more of the foregoing covenants or extend the time for their performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B>Payment of
Expenses</B><B>.</B> The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation
(i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue,
transfer and other stamp taxes in connection with the issuance and sale of the Offered Shares to the Underwriters and any taxes or duties imposed under the laws of Cayman Islands in connection with the resale and delivery of the Offered Shares by
the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus and each preliminary prospectus, each Permitted <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the
Company or the Underwriters in connection with qualifying or registering (or obtaining </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemptions from the qualification or registration of) all or any part of the Offered Shares for offer and sale under the state securities or blue sky laws, and, if requested by the
Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the
costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares,
including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, such expenses not to exceed $25,000, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road
show&#148;, any Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any Oral <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication undertaken in connection with the offering of the Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road
show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company
and any such consultants, and the cost of any aircraft chartered in connection with the road show, (ix)&nbsp;the fees and expenses associated with listing the Offered Shares on the Nasdaq, and (x)&nbsp;all other fees, costs and expenses of the
nature referred to in Item 14 of Part&nbsp;II of the Registration Statement. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees
and disbursements of their counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B>Covenant of the Underwriters</B><B>.</B> Each Underwriter
severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on
behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B>Conditions of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the
several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and
warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the
timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from Ernst&nbsp;&amp; Young LLP,
independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included
in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial
information contained in the Registration Statement and the Time of Sale Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Compliance with Registration
Requirements; No Stop Order; No Objection from </I></B><B><I>FINRA</I></B><B><I>. </I></B>For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased
after the First Closing Date, each Option Closing Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the
Commission (including the information previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the
underwriting terms and arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period
from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as that term is used in <FONT STYLE="white-space:nowrap">Rule&nbsp;15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Opinion of Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the
Representatives shall have received the opinion and negative assurance letter of (i)&nbsp;Davis Polk&nbsp;&amp; Wardwell LLP, U.S. counsel for the Company, and (ii)&nbsp;Walkers (Cayman) LLP, Cayman Islands counsel for the Company, dated as of such
date, in form and substance satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Opinion of </I></B><B><I>Intellectual Property Counsel
for the Company</I></B><B><I>.</I></B><I> </I>On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Company with
respect to intellectual property, dated as of such date, in form and substance satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)
</B><B><I>Opinion of Counsel for the Underwriters</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion and negative assurance letter of Paul Hastings LLP, counsel for the
Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory to the Underwriters, dated as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Officers&#146; Certificate</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the
Representatives shall have received a certificate executed by the Chief Executive Officer of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the
effect that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of this Agreement through and including such date, there has
not occurred any Material Adverse Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties and covenants of the Company set forth in
Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed
or satisfied hereunder at or prior to such date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Bring-down Comfort Letter</I></B><B>.</B> On each of the First Closing Date
and each Option Closing Date the Representatives shall have received from Ernst&nbsp;&amp; Young LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives,
which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days
prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>) </B><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B><I>.</I></B> On or prior to the date
hereof, the Company shall have furnished to the Representatives an agreement in the form of <U>Exhibit A</U> hereto from each of the persons listed on <U>Exhibit B</U> hereto, and each such agreement shall be in full force and effect on each of the
First Closing Date and each Option Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;462(b) Registration
Statement</I></B>. In the event that a Rule&nbsp;462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b) Registration Statement shall have been filed with the Commission on the
date of this Agreement and shall have become effective automatically upon such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Reserved. </I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Additional Documents</I></B>. On or before each of the First Closing Date and each Option Closing Date, the Representatives
and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in
order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the
Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>. If this Agreement is terminated by the
Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the
Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves),
severally, upon demand for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the
proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. </B><B>Effectiveness of this Agreement</B>. This Agreement
shall become effective upon&nbsp;the execution and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.
</B><B>Indemnification</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold
harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or
expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the
laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as
such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of
a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any Marketing Material, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the
Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not
misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or
referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or (ii) above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and
controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense
to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any Marketing Material, any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in
Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any
loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as
contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary
in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission
was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the Prospectus (or any
such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director,
officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the Prospectus (or any amendment or supplement to the
foregoing) are the concession figures appearing in the fifth paragraph under the caption &#147;Underwriting&#148; and the information relating to stabilizing transactions, syndicate covering transactions and penalty bids contained in the paragraphs
under the caption &#147;Underwriting&#151;Stabilization&#148; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that each
Underwriter may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Notifications and Other Indemnification Procedures</I></B><B>.</B> Promptly after
receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the
indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying
party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is
brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other
indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such
indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the
positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available
to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon
receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to
such indemnified party under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in
accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the
indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in
Section&nbsp;9(a) above) or by </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the
indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the
expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or
expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such
indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and
indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such
action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10. </B><B>Contribution</B>. If the indemnification provided for in Section&nbsp;9 is for any reason held to be
unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or
payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the
one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which
resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with
the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by
the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set
forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any
action or claim. The provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided, however,</I> that no additional notice
shall be required with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and
distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes
of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to
contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act
shall have the same rights to contribution as the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. </B><B>Default of One or More of the Several
Underwriters</B><I>.</I> If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the
aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may
make arrangements satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and
not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <U>Schedule</U><B><U> </U></B><U>A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the
Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase
Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the
Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7,
Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to include any person substituted for a defaulting
Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12. </B><B>Termination of this Agreement</B><I>.</I> Prior to
the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s
securities shall have been suspended or limited by the Commission or by the Nasdaq, or trading in securities generally on either the Nasdaq or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have
been generally established on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or
international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international
political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the
Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood,
earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been
insured. Any termination pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the
Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. </B><B>No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that
(a)&nbsp;the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its shareholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will
assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14. Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on
behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Offered
Shares sold hereunder and any termination of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15. </B><B>Notices</B>. All communications hereunder shall be
in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Representatives:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jefferies LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">619-4437</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">J.P. Morgan Securities LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">383 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10179</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (212) <FONT STYLE="white-space:nowrap">622-8358</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Equity Syndicate Desk</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Guggenheim Securities, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">330 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (212) <FONT STYLE="white-space:nowrap">658-9689</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Head of Equity Capital Markets</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paul Hastings LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The MetLife Building</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">200 Park Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10166</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Siavosh Salimi and William A. Magioncalda</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ProKidney Corp.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2000 Frontis Plaza Blvd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Suite 250</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Winston-Salem, North Carolina 27103</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Bruce Culleton, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Davis Polk&nbsp;&amp; Wardwell LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">450 Lexington Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Richard Truesdell</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16. </B><B>Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties
hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each
case their respective successors, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by reason of
such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17. </B><B>Partial Unenforceability</B>. The invalidity or unenforceability of any section,
paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or
unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Recognition of the U.S. Special Resolution Regimes.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>In the event
that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 382.2(b); (C) &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#147;<B>U.S. Special Resolution
Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19. Governing Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in accordance
with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby
(&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough
of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such
court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable
law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect
to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding
or Related Judgment, including, without limitation, any immunity pursuant to the courts of the Cayman Islands or the United States Foreign Sovereign Immunities Act of 1976, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20. </B><B>General Provisions</B><B>.</B> This Agreement
constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be
executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any
electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method, and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied)
may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>PROKIDNEY CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bruce Culleton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bruce Culleton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>J.P. MORGAN SECURITIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>GUGGENHEIM SECURITIES, LLLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Acting individually and as Representatives of the several Underwriters named in the attached <U>Schedule A</U>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Sheridan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Kevin Sheridan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Global Joint Head of Healthcare Investment Banking</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>J.P. MORGAN SECURITIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Ke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>David Ke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>GUGGENHEIM SECURITIES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Burkly</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Thomas Burkly</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,601,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,601,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,403,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PJT Partners LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,137,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,744,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Roadshow Presentation dated June 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June ____, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GUGGENHEIM SECURITIES, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the Several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC&#8195; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Guggenheim Securities, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">330 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney Corp. (the &#147;<B>Company</B>&#148;) </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Ladies</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&amp; Gentlemen: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an owner of Class&nbsp;A ordinary shares, par value $0.0001 per share, of the Company (the &#147;<B>Class</B><B></B><B>&nbsp;A Ordinary
Shares</B>&#148;) and/or Class&nbsp;B ordinary shares, par value $0.0001 per share, of the Company (the &#147;<B>Class</B><B></B><B>&nbsp;B Ordinary Shares</B>&#148; and, together with the Class&nbsp;A Ordinary Shares, the &#147;<B>Shares</B>&#148;)
or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the &#147;<B>Offering</B>&#148;) for which Jefferies LLC (&#147;<B>Jefferies</B>&#148;), J.P. Morgan Securities
LLC (&#147;<B>J.P. Morgan</B>&#148;) and Guggenheim Securities, LLC will act as the representatives of the underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;). The undersigned recognizes that the Offering will benefit each of the
Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering
into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company with respect to the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement. Those definitions are a
part of this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will cause any Family Member not to), without the prior written consent of Jefferies and J.P. Morgan,
which may withhold their consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements
(including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or
intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of
any Shares or Related Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Shares or Related Securities, in cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing restrictions shall not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Shares or Related Securities by gift to a Family Member or to a trust whose beneficiaries
consist exclusively of one or more of the undersigned and/or a Family Member;<I>&nbsp;provided</I>&nbsp;that (A)&nbsp;such transfer is not for value, (B)&nbsp;if required during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any public
report or filing shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances described in this clause (i), and (C)&nbsp;the undersigned does not otherwise voluntarily effect any other public filing
or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Shares or Related Securities by will or intestate succession to a Family Member or to a trust
whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of Shares or Related Securities by operation of law, or pursuant to an order of a court or regulatory
agency, including pursuant to a domestic order or divorce settlement;<I>&nbsp;provided</I>&nbsp;that (A)&nbsp;if required during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any public report or filing shall clearly indicate in the
footnotes thereto that such transfer is being made pursuant to the circumstances described in this clause (iii), and (B)&nbsp;the undersigned does not otherwise voluntarily effect any other public filing or report regarding such transfers during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of the undersigned&#146;s Shares or Related Securities to any corporation, partnership, limited
liability company or other entity all of the beneficial ownership interests of which, in each case, are held by the undersigned and such transfer is not for value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity,
the transfer of Shares or Related Securities made by the undersigned to another corporation, partnership, limited liability company, trust or other business entity so long as the transferee is an Affiliate of the undersigned and such transfer is not
for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise of share options or other performance or share rights to acquire Shares and/or Related Securities
granted under the Company&#146;s equity incentive plans described in the prospectus relating to the Offering (the &#147;<B>Prospectus</B>&#148;) by the undersigned, and the receipt by the undersigned from the Company of Shares and/or Related
Securities upon such exercise, insofar as such share option or right is outstanding as of the date of the Prospectus,<I>&nbsp;provided</I>&nbsp;that the underlying Shares and/or Related Securities shall continue to be subject to the restrictions on
transfer set forth in this letter agreement, and<I>&nbsp;provided further</I>, if required during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any public report or filing shall clearly indicate in the footnotes thereto that the filing
relates to the exercise of a share option or right and that no Shares or Related Securities were sold by the reporting person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of Shares or Related Securities to the Company (A)&nbsp;to satisfy tax withholding and
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
remittance obligations of the undersigned in connection with the vesting or exercise of equity awards granted pursuant to the Company&#146;s equity incentive plans; or (B)&nbsp;pursuant to a net
exercise or cashless exercise by the undersigned of outstanding equity awards pursuant to the Company&#146;s equity incentive plans,<I>&nbsp;provided</I>&nbsp;that any Shares or Related Securities received as a result of such exercise, vesting or
settlement shall remain subject to the terms of this letter agreement, and<I>&nbsp;provided further</I>, if required during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any public report or filing shall clearly indicate in the
footnotes thereto that such transfer is being made pursuant to the circumstances described in this clause (vii); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Shares or Related Securities pursuant to a bona fide third party tender offer, merger,
consolidation or other similar transaction made to all holders of the Shares involving a Change of Control of the Company, <I>provided</I> that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the
Shares and Related Securities owned by the undersigned shall remain subject to the restrictions contained in this letter agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of Shares or Related Securities to the Company in connection with the repurchase of such Shares or
Related Securities by the Company upon the termination of the undersigned&#146;s employment or other service with the Company pursuant to agreements under which the Company has the option to repurchase such Shares or Related Securities as in in
effect as of the date of the Prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a trading plan established pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under
the Exchange Act (a &#147;<B><FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan</B>&#148;) prior to the date hereof, which trading plan shall not be amended during the Restricted Period but may be terminated during the Restricted Period;
<I>provided</I> that (A)&nbsp;if required during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any public report or filing shall clearly indicate in the footnotes thereto that such transfer is being made pursuant to the circumstances
described in this clause (x), and (B)&nbsp;the undersigned does not otherwise voluntarily effect any other public filing or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the case of any transfer described in clauses (i), (ii), (iv) and (v)&nbsp;above, it shall be a condition to such transfer
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each transferee executes and delivers to the Representatives an agreement in form and substance satisfactory to
the Representatives stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage
in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in the case of clause (i)&nbsp;above, prior to the expiration of the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in
beneficial ownership of Shares or Related Securities in connection with such transfer. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions
imposed by this letter agreement, the undersigned may establish a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Shares and/or Related Securities,<I>&nbsp;provided </I>that
(x)&nbsp;such plan does not permit dispositions or sales of Shares or any Related Securities during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and (y)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any,
is required by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Shares or Related Securities may be made under such plan
during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants
that no single natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act), other than a natural person, entity or &#147;group&#148; (as described above) that has executed a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement in substantially the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same form as this letter agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer
of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take,
directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment
advice nor have the underwriters solicited any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The
undersigned further acknowledges and agrees that, although the underwriters may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the underwriters are not making a
recommendation to you to enter into this letter agreement or participate in this Offering, and nothing set forth in such disclosures is intended to suggest that the underwriters are making such a recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors. The Offering will only be made pursuant
to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby
represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives
and assigns of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Company notifies the Representatives in writing that it does not intend to proceed with the Offering,
(ii)&nbsp;the Underwriting Agreement is not executed by June&nbsp;21, 2024, or (iii)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for
and delivery of Shares to be sold thereunder, then this letter agreement shall immediately be terminated and the undersigned shall automatically be released from all obligations under this letter agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000, e.g. <U>www.docusign.com</U> or <U>www.echosign.com</U>) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed Name of Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Certain Defined Terms </U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Affiliate</B>&#148; shall have the meaning set forth in Rule 405 under the Securities Act.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Call Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Change of Control</B>&#148; means the consummation of any bona fide third party tender offer, merger,
consolidation or other similar transaction approved by the Board of Directors of the Company, the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company
or its subsidiaries, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of 100% of the total voting power of the voting stock of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Exchange Act</B>&#148; shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member
may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth
in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; shall mean the period beginning on the
date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any
securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call
Equivalent Position, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other way transfer or dispose of, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this letter agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors, Officers and Certain Shareholders </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signing <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bruce Culleton, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pablo Legorreta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William F. Doyle </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alan M. Lotvin, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian J. G. Pereira, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uma Sinha, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jose Ignacio Jimenez Santos </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Fox </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Coulston, CPA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Darin J. Weber, Ph. D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Todd Girolamo, J.D., MBA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ulrich Ernst, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Control Empresarial de Capitales S.A. de C.V. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d814183dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g814183g55h99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">13&nbsp;June 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Our Ref: JA/CBY/CM/179141</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProKidney Corp.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Walkers Corporate
Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">190 Elgin Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">George Town</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9008</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cayman Islands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Addressees </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROKIDNEY
CORP. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been asked to provide this legal opinion to you with regards to the laws of the Cayman Islands in connection with a Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed on the date hereof (the &#147;<B>Registration Statement</B>&#148;) by ProKidney Corp. (the &#147;<B>Company</B>&#148;) under the United States Securities Act of 1933, as amended
(the &#147;<B>Securities Act</B>&#148;), and the Prospectus Supplement (as defined in Schedule 1) thereto relating to the offering, issue, and sale (the &#147;<B>Offering</B>&#148;) by the Company of 53,774,794 of the Company&#146;s Class&nbsp;A
ordinary shares of a par value $0.0001 per share, and up to 6,411,633 additional Class&nbsp;A ordinary shares pursuant to the Underwriters&#146; option to purchase additional Class&nbsp;A ordinary shares (each a &#147;<B>Share</B>&#148; and
collectively, the &#147;<B>Shares</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of giving this opinion, we have examined and relied upon the originals or copies of the
documents listed in Schedule 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are Cayman Islands Attorneys at Law and express no opinion as to any laws other than the laws of the Cayman Islands in
force and as interpreted at the date of this opinion. We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing examinations and the assumptions and qualifications set out below and having regard to legal considerations which we consider
relevant, and under the laws of the Cayman Islands, as at the date hereof, we give the following opinion in relation to the matters set out below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is an exempted company duly incorporated with limited liability, validly existing under the laws of
the Cayman Islands and in good standing with the Registrar of Companies in the Cayman Islands (the &#147;<B>Registrar</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares have been duly authorised by all necessary corporate action of the Company. Upon the issue of the
Shares (by the entry of the name of the registered owner thereof in the Register of Members of the Company confirming that such Shares have been issued credited as fully paid), delivery and payment therefore by the purchaser (for consideration not
being less than their par value) in accordance </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Walkers </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">190 Elgin Avenue, George Town </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Grand
Cayman KY1-9001, Cayman Islands </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>T</B> +1 345 949 0100 <B>F</B> +1 345 949 7886 <U>www.walkersglobal.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Bermuda | British Virgin Islands | Cayman Islands | Dubai | Guernsey | Hong Kong | Ireland | Jersey | London | Singapore </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with the Memorandum and Articles of Association (as defined in Schedule 1) and the Underwriting Agreement (as defined in Schedule 1) or a Share Purchase Agreement, as the case may be, and in the
manner contemplated by the Prospectus Supplement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (meaning that no additional sums may be levied in respect of the Shares on the holder thereof
by the Company). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing opinions are given based on the following assumptions and subject to the following qualifications: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The originals of all documents examined in connection with this opinion are authentic. The signatures, initials
and seals on the documents reviewed by us are genuine and are those of a person or persons with power to execute the documents. All documents purporting to be sealed have been so sealed. All copies are complete and conform to their originals.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have relied upon the statements and representations of directors, officers and other representatives of the
Company as to factual matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All information contained in the Registration Statement and all other documents reviewed by us is true and
correct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Memorandum and Articles of Association (as defined in Schedule 1) reviewed by us will be the memorandum and
articles of association of the Company in effect upon the issuance of the Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Prospectus Supplement, each Share Purchase Agreement and the documents or agreements referred to therein,
will be duly authorised, executed and delivered by or on behalf of all relevant parties prior to the issue and sale of the Shares and will be legal, valid, binding and enforceable against all relevant parties in accordance with their terms.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will offer, issue and sell the Shares in the manner contemplated by the Prospectus Supplement and
the documents or agreements referred to therein and otherwise in compliance with all applicable United States federal and state securities laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company Records (as defined in Schedule 1) are complete and accurate and all matters required by law and
the Memorandum and Articles of Association to be recorded therein are completely and accurately so recorded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will receive consideration in money or money&#146;s worth for each of the Shares when issued, such
price in any event not being less than the stated par value of each Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Resolutions (as defined in Schedule 1) are and shall remain in full force and effect and have not been and
will not be rescinded or amended. The Resolutions have been duly executed by or on behalf of each Director and the signatures and initials thereon are those of a person or persons in whose name the Resolutions have been expressed to be signed.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Documents have been duly authorised, executed and delivered by or on behalf of all relevant parties and
will constitute legal, valid, binding and enforceable obligations against all relevant parties in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The choice of the laws of the jurisdiction selected to govern each of the Documents, has been made in good
faith and will be regarded as a valid and binding selection which will be upheld in the courts of that jurisdiction and all relevant jurisdictions (other than the Cayman Islands). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The issue of the Shares will be of commercial benefit to the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No invitation has been made or will be made by or on behalf of the Company to the public in the Cayman Islands
to subscribe for any of the Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company was, or will be, on the date of execution of the Documents to which it is a party able to pay its
debts as they became due from its own moneys, and any disposition or settlement of property effected by any of the Documents is or will be made in good faith and for valuable consideration and at the time of each disposition of property by the
Company pursuant to the Documents the Company will be able to pay its debts as they become due from its own moneys<B><I>.</I></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No amounts paid to or for the account of any party under the Documents or any property received or disposed of
by any party to the Documents in each case in connection with the performance of the Documents or the consummation of the transactions contemplated thereby, represent or will represent proceeds of criminal conduct or criminal property as defined in
the Proceeds of Crime Act (as amended) (the &#147;<B>POCA</B>&#148;) or terrorist property as defined in the POCA or the Terrorism Act (as amended) (the &#147;<B>Terrorism Act</B>&#148;), each of the Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no provisions of the laws of any jurisdiction outside the Cayman Islands which would be contravened
by the issuance and allotment of the Shares and, insofar as any obligation expressed to be incurred under any Document or other document or agreement under the terms of which the Company has agreed to issue the Shares is to be performed in or is
otherwise subject to the laws of any jurisdiction outside the Cayman Islands, its performance will not be illegal by virtue of the laws of that jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is nothing under any law (other than the laws of the Cayman Islands) which would or might affect any of
the opinions set forth above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company on the date hereof, on the date of entry into the Documents under the terms of which the Company
has agreed to issue the Shares and on the issuance of the Shares will be able to pay its debts as they became due from its own moneys. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our opinion as to good standing is based solely upon receipt of the Certificate of Good Standing (as defined in
Schedule 1) issued by the Registrar. The Company shall be deemed to be in good standing under section 200A of the Companies Act (as amended) of the Cayman Islands (the &#147;<B>Companies Act</B>&#148;) on the date of issue of the certificate if all
fees and penalties under the Companies Act have been paid and the Registrar has no knowledge that the Company is in default under the Companies Act. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term &#147;<B>enforceable</B>&#148; and its cognates as used in this opinion means that the obligations
assumed by any party under the Documents are of a type which the the courts of the Cayman Islands (the &#147;<B>Courts</B>&#148; and each a &#147;<B>Court</B>&#148;) enforce. This does not mean that those obligations will necessarily be enforced in
all circumstances in accordance with their terms. In particular: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforcement of obligations and the priority of obligations may be limited by bankruptcy, insolvency,
liquidation, restructuring, reorganisation, readjustment of debts or moratorium and other laws of general application relating to or affecting the rights of creditors or by prescription or lapse of time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforcement may be limited by general principles of equity and, in particular, the availability of certain
equitable remedies such as injunction or specific performance of an obligation may be limited where a Court considers damages to be an adequate remedy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">claims may become barred under statutes of limitation or may be or become subject to defences of <FONT
STYLE="white-space:nowrap">set-off,</FONT> counterclaim, estoppel and similar defences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where obligations are to be performed in a jurisdiction outside the Cayman Islands, they may not be enforceable
in the Cayman Islands to the extent that performance would be illegal under the laws of, or contrary to the public policy of, that jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a judgment of a Court may be required to be made in Cayman Islands dollars; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that any provision of the Documents is adjudicated to be penal in nature, it will not be
enforceable in the Courts; in particular, the enforceability of any provision of the Documents that is adjudicated to constitute a secondary obligation which imposes a detriment on the contract-breaker out of all proportion to any legitimate
interest of the innocent party in the enforcement of the primary obligation may be limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that the performance of any obligation arising under the Documents would be fraudulent or
contrary to public policy, it will not be enforceable in the Courts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an insolvent liquidation of the Company, its liabilities are required to be translated into the
functional currency of the Company (being the currency of the primary economic environment in which it operated as at the commencement of the liquidation) at the exchange rates prevailing on the date of commencement of the voluntary liquidation or
the day on which the winding up order is made (as the case may be); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Court will not necessarily award costs in litigation in accordance with contractual provisions in this
regard; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effectiveness of terms in the Documents excusing any party from a liability or duty otherwise owed or
indemnifying that party from the consequences of incurring such liability or breaching such duty shall be construed in accordance with, and shall be limited by, applicable law, including generally applicable rules and principles of common law and
equity. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters referred to herein and shall not be construed as extending to any
other matter or document not referred to herein.&nbsp;This opinion is given solely for your benefit and the benefit of your legal advisers acting in that capacity in relation to this transaction and may not be relied upon by any other person, other
than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without our prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion shall be
construed in accordance with the laws of the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to the Form <FONT
STYLE="white-space:nowrap">8-K</FONT> incorporated by reference into the Registration Statement and/or Prospectus Supplement and further consent to all references to us in the Registration Statement and/or Prospectus Supplement and any amendments
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Walkers (Cayman) LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS (CAYMAN) LLP </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF DOCUMENTS EXAMINED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Certificate of Incorporation dated 25&nbsp;February 2021, Certificate of Incorporation on Change of Name
dated 11&nbsp;July 2022, the Second Amended and Restated Memorandum and Articles of Association of the Company as adopted on 11&nbsp;July 2022 (the &#147;<B>Memorandum and Articles of Association</B>&#148;) and each of the Register of Directors,
Register of Officers and Register of Mortgages and Charges of the Company (together, the &#147;<B>Company Records</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cayman Online Registry Information System (CORIS), the Cayman Islands&#146; General Registry&#146;s online
database, searched on 12&nbsp;June 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Certificate of Good Standing dated 13&nbsp;June 2024 in respect of the Company issued by the Registrar (the
&#147;<B>Certificate of Good Standing</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of the executed written resolutions of the Directors of the Company dated 17&nbsp;November 2023 and
7&nbsp;June 2024 (the &#147;<B>Resolutions</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Copies of the following documents (the &#147;<B>Documents</B>&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a preliminary prospectus supplement to the Registration Statement relating to the issuance and sale of the
Shares (the &#147;<B>Preliminary Prospectus Supplement</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a final prospectus supplement to the Registration Statement relating to the issuance and sale of the Shares
(together with the Preliminary Prospectus Supplement, the &#147;<B>Prospectus Supplement</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the executed Underwriting Agreement dated 11&nbsp;June 2024 among the Company and the Underwriters named
therein relating to the issuance and sale of the Shares in the underwritten public offering (the &#147;<B>Underwriting Agreement</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a form of Share Purchase Agreement among the Company and such investor named therein relating to the issuance
and sale of the Shares in the registered direct offering (such form, a &#147;<B>Share Purchase Agreement</B>&#148;). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d814183dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain identified information has been excluded from this exhibit pursuant to Item 601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> because it is both not material and is the type of information that the Registrant treats as confidential. Information that was omitted has been noted with a placeholder identified by the mark &#147;[***]&#148;
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">June&nbsp;11, 2024 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ProKidney Corp., a Cayman Islands exempted company (the &#147;Company&#148;), and each of the undersigned investors (each, an
&#147;Investor&#148;), severally and not jointly, are entering into this Share Purchase Agreement (this &#147;Agreement&#148;) pursuant to which the Company will sell to each Investor, and each Investor will purchase from the Company, the number of
Class&nbsp;A ordinary shares (the &#147;Purchased Shares&#148;), par value $0.0001 per share (the &#147;Ordinary Shares&#148;), of the Company, set forth on the signature page of such Investor at the public offering price set forth in the Final
Prospectus Supplement (as defined below) per Purchased Share set forth thereon (the number of Purchased Shares to be purchased by such Investor multiplied by such price, the &#147;Purchase Amount&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the &#147;Commission&#148;) a shelf registration statement on
Form <FONT STYLE="white-space:nowrap">S-3,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275701,</FONT> including a base prospectus (the &#147;Base Prospectus&#148;) to be used in connection with the offering and sale of the Purchased
Shares. Such registration statement, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, and the rules and regulations promulgated thereunder (collectively,
the &#147;Securities Act&#148;), including all documents incorporated or deemed to be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A or 430B under the Securities
Act, is called the &#147;Registration Statement.&#148; As used herein, the term &#147;Prospectus&#148; shall mean the final prospectus supplement to the Base Prospectus that describes the offering and sale of the Purchased Shares (the &#147;Final
Prospectus Supplement&#148;), together with the Base Prospectus, in the form first made available to the Investors by the Company to meet the requirements of Rule 173(b) under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, &#147;Applicable Time&#148; is 9:00 p.m. (New York City time) on June&nbsp;11, 2024. As used herein, &#147;Time of Sale
Prospectus&#148; means the Base Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the pricing information set forth on the signature pages hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which are &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all
such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to amendments or supplements to the Registration Statement, the Base Prospectus, the Time of Sale Prospectus
or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder (collectively, the &#147;Exchange Act&#148;) that is or is deemed to be
incorporated by reference in the Registration Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the Base Prospectus or the Prospectus, any amendments or supplements to any of
the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&#147;EDGAR&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection therewith, and in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the
conditions, set forth herein, and intending to be legally bound hereby, the Company and each Investor acknowledge and agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Purchase and Sale</U>. The Company hereby agrees to issue and sell to each Investor, and each Investor hereby agrees, severally and not jointly, to purchase from the Company, the number of Purchased Shares set forth on the signature page of this
Agreement and to pay its Purchase Amount on the terms and subject to the conditions provided for herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Closing; Closing Deliverables</U>. The purchase, sale and issuance of the Purchased
Shares shall take place on June&nbsp;13, 2024 or at such other date, time or place as the parties may mutually agree in writing (the &#147;Closing&#148; and such date, the &#147;Closing Date&#148;). On the Closing Date, (a)&nbsp;the Company will
have delivered, or cause to be delivered, such irrevocable instructions and opinions of counsel required to be delivered to effectuate the delivery by Continental Stock Transfer&nbsp;&amp; Trust Company (the &#147;Transfer Agent&#148;) of the
Purchased Shares to the Investors through the facilities of the Depository Trust Company in accordance with the instructions set forth on such Investor&#146;s signature page attached hereto and (b)&nbsp;each Investor, in full payment for the
Purchased Shares, will deliver or cause to be delivered to the Company immediately available funds by wire transfer to the account set forth below, in an amount equal to the Purchase Amount: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Bank Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">SWIFT:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Account Holder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Account No.:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Routing Number:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On or prior to the Closing Date, the Company shall have delivered to each Investor (i)&nbsp;the Prospectus
(which may be delivered in accordance with Rule 172 under the Securities Act) and (ii)&nbsp;a certificate signed by the Chief Executive Officer, the Chief Financial Officer or another authorized officer of the Company to the effect that all of the
conditions set forth in Section&nbsp;6 have been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company
represents and warrants to each Investor as of the Applicable Time and the Closing Date, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Compliance with Registration
Requirements</U>. At the time the Registration Statement was originally declared effective, and at the time the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> was filed with the Commission, the Company
met the then applicable requirements for the use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, including General Instruction I.B.1 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The Company is not a shell
company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined in
Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3)</FONT> with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Misstatement or Omission</U>. The Prospectus when filed complied and, as amended or supplemented, if applicable, will comply in all
material respects with the Securities Act. Each of the Registration Statement, the Prospectus and any post-effective amendments or supplements thereto, at the time it became effective or its date, as applicable, complied and at the time of each sale
of the Purchased Shares and at the Closing Date, the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus, as amended or supplemented, as of its date, did not and, at the Closing Date, will not contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. There are no contracts or other documents required to be described in the
Registration Statement, the Time of Sale Prospectus and the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Incorporation and Good Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a corporation in
good standing (where such concept is recognized) under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in each jurisdiction in
which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing, as the case may be, would not result in a material adverse
change, or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any development that would reasonably be expected to result in a material adverse change, on or affecting the assets, business, operations, earnings, properties, condition (financial or
otherwise), prospects, shareholders&#146; equity or results of operations of the Company and its subsidiaries taken as a whole, or prevent or materially interfere with consummation of the transactions contemplated hereby (any such change, a
&#147;Material Adverse Change&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Authorization; Enforceability</U>. The Company has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement and to issue the Purchased Shares in accordance with the terms hereof. This Agreement has been duly executed and delivered by the Company and constitutes a valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or
similar laws relating to, or affecting generally the enforcement of, creditor&#146;s rights and remedies or by other equitable principles of general application (including any limitation of equitable remedies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Authorization of the Ordinary Shares</U>. The Purchased Shares, when sold and issued (by entry of the name of the registered owner
therefor in the Register of Members of the Company confirming that such Purchased Shares have been issued and credited as fully paid) against payment therefor in accordance with this Agreement, shall be validly issued and outstanding, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all liens, charges, taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof. Upon
issuance in accordance with the terms of this Agreement, the Purchased Shares will be freely tradable by each Investor on the Nasdaq Capital Market (the &#147;Nasdaq&#148;) without restriction (assuming such investor is not an &#147;affiliate&#148;
within the meaning of Rule 405 promulgated under the Securities Act), and the Shares shall not bear any restrictive legends (electronic or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of the Investors</U>. Each Investor, for itself and for no other Investor, represents, warrants,
acknowledges and agrees, as of the Applicable Time and the Closing Date, that: (i)&nbsp;it is duly organized, validly existing and in good standing (as applicable) under the laws of the jurisdiction that governs it, and is duly qualified to do
business and in good standing in each jurisdiction where such qualification is required and has all requisite power and authority to own, operate and lease its properties and to carry on its business as it is being conducted on the date of this
Agreement; (ii)&nbsp;it is neither in bankruptcy, liquidation or receivership (and no order or resolution therefore has been presented and no notice of appointment of any liquidator, receiver, administrative receiver or administrator has been
given), nor are there any valid grounds or circumstances on the basis of which any such procedure may be requested on a voluntary or involuntary basis by any entity; (iii)&nbsp;it has the legal right and power to enter into this Agreement and to
purchase all rights and interest in the number of Purchased Shares as set forth on such Investor&#146;s signature page hereto pursuant to this Agreement and to comply with its other obligations hereunder; (iv)&nbsp;this Agreement and any other
documents required to be signed by such Investor hereunder have been duly authorized (or, in the case of documents to be executed and delivered at the Closing, will have been duly authorized by all necessary action on the part of such Investor),
executed and delivered by or on behalf of such Investor; and, assuming due authorization, execution and delivery by the other parties thereto, this Agreement and all documents required hereunder to be executed by such Investor constitute or will
constitute, in the case of documents to be executed and delivered at the Closing, the legally valid and binding obligations of such Investor, enforceable against such Investor in accordance with its terms, except that such enforceability
(A)&nbsp;may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting or relating to the enforcement of creditors&#146; rights generally and (B)&nbsp;is subject to
general principles of equity, whether considered in a proceeding at law or in equity; (v)&nbsp;the entry into, execution, delivery and performance of this Agreement does not infringe any contractual, organizational or legal obligation (including any
marital obligation or agreement) of such Investor; (vi)&nbsp;the entry into, execution, delivery and performance of this Agreement does not require (A)&nbsp;any consent, approval, order or authorization of or other action by any governmental entity,
or any registration, qualification, declaration or filing (other than any filings required to be made with the Commission) under the Securities Act, or the Exchange Act; or (B)&nbsp;on the part of such Investor, any consent by or approval of or
notice to any other person or entity (other than a governmental entity), the absence or omission of which would, either individually or in the aggregate, breach any marital obligation or agreement or have a material adverse effect on such
Investor&#146;s ability to consummate the transactions contemplated hereby (vii)&nbsp;other than pursuant to the separate <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements entered into by the Company, on the one hand, and each other
party hereto, on the other (the &#147;Confidentiality Agreements&#148;), in connection with the transactions contemplated by this Agreement, there have been no representations, warranties, covenants and agreements made
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to this Agreement and the transactions contemplated hereby to such Investor by or on behalf of the Company or any of their respective affiliates or any control persons, officers,
directors, employees, partners, agents or representatives of any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements set forth herein; (viii)&nbsp;such
Investor has independently, without reliance upon the Company and based on such information as it deemed appropriate, investigated the current business and financial condition of the Company and its subsidiaries and the circumstances surrounding the
sale and purchase of the Purchased Shares in order to make an investment decision with respect to the Purchased Shares, and such Investor has had the opportunity to review the Company&#146;s filings with the Commission and such other information as
has been requested by such Investor and provided by the Company; (ix)&nbsp;such Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Purchased
Shares, and such Investor has sought and received such accounting, legal and tax advice as such Investor has considered necessary to make an informed investment decision and such Investor has independently, without reliance upon the Company and
based on such information as it deemed appropriate, such Investor has made its own assessment and has satisfied itself concerning relevant tax and other economic considerations relative to its purchase of the Purchased Shares, and such Investor is
able to sustain a complete loss on its investment in the Purchased Shares; (x)&nbsp;such Investor is familiar with the limitations imposed upon a recipient of material <FONT STYLE="white-space:nowrap">non-public</FONT> information under applicable
securities laws; (xi)&nbsp;when required to deliver payment to the Company, such Investor will have sufficient funds to pay the Purchase Amount and consummate the purchase and sale of the Purchased Shares pursuant to this Agreement; (xii)&nbsp;there
is no proceeding, pending or, to the knowledge of such Investor, threatened, against it or its subsidiaries, that would reasonably be expected to impair in any respect the ability of such Investor to perform its obligations hereunder or prevent,
prohibit, restrict or materially delay the consummation of the transactions contemplated by this Agreement; (xiii)&nbsp;such Investor and its officers, directors, and employees are in compliance, in all material respects, with sanctions and
applicable anti-corruption laws and anti-money laundering laws, and neither Investor nor any of its officers, directors, or employees is a sanctioned person; and (xiv)&nbsp;as to Investors of Mexican nationality, they are &#147;qualified
investors&#148; (<I>inversionistas calificados</I>) or &#147;institutional investors&#148; (<I>inversionistas institucionales</I>) (as such terms are defined in applicable Mexican regulations), and they acknowledge that (a)&nbsp;the Purchased Shares
have not been and will not be registered with the Mexican National Registry of Securities (<I>Registro Nacional de Valores</I>) maintained by the Mexican National Banking and Securities Commission (<I>Comision Nacional Bancaria y de Valores</I>, or
the &#147;CNBV&#148;) and, therefore, may not be offered or sold publicly in Mexico, (b)&nbsp;the Company has not publicly disseminated or disclosed, and is not permitted to publicly disseminate or disclose, the Prospectus (or any amendments or
supplements thereto) and any documents or information related to the offering or sale of the Purchased Shares in Mexico, and (c)&nbsp;the information in the Prospectus (or any amendments or supplements thereto) has not been and will not be reviewed
or authorized by the CNBV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Additional Covenants</U>. The Company further covenants and agrees with each Investor as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to an Investor, not misleading, the Company agrees to promptly prepare, file with the Commission
and furnish, at its own expense, to the Investors upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to an
Investor, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Use of
Proceeds</U>. The Company shall apply the net proceeds from the sale of the Purchased Shares sold by it in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Purchased Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Earnings Statement</U>. The Company will make generally available to its security
holders as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the
provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. For the avoidance of doubt, the Company&#146;s compliance with the reporting requirements of the Exchange Act shall be deemed to
satisfy the requirements in the immediately preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Continued Compliance with Securities Laws</U>. The Company will
comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Purchased Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus.
Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Purchased Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under
the Securities Act or any similar rule), file on a timely basis with the Commission and the Nasdaq all reports and documents required to be filed under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Listing</U>. The Company will use its reasonable best efforts to list, subject to notice of issuance, the Purchased Shares on the
Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Investment Limitation</U>. The Company shall not invest or otherwise use the proceeds received by the Company from its
sale of the Purchased Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>No Stabilization or Manipulation; Compliance with Regulation M</U>. The Company will not take, and will ensure that no affiliate of the
Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Ordinary Shares or any reference security with respect to the Ordinary Shares, whether to facilitate
the sale or resale of the Purchased Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Disclosure of Transactions and Other Material Information</U>. The Company shall, on or before 8:30 a.m., New York City time, on the
second business day after the date of this Agreement (or if this Agreement is executed between midnight and 9:00 a.m., New York City time, no later than 9:01 a.m., New York City time, on the first business day after the date of this Agreement),
issue a press release, file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and/or file the Final Prospectus Supplement (any such communication, a &#147;Cleansing Release&#148;) disclosing all the material terms of the
transactions contemplated hereby. From and after the issuance or filing of the Cleansing Release, the Company shall have disclosed all material, nonpublic information delivered to the Investors by the Company or any of its Subsidiaries, or any of
their respective officers, directors, employees or agents (if any) in connection with the transactions contemplated by this Agreement. In addition, effective upon the issuance or filing of the Cleansing Release, the Company acknowledges and agrees
that any and all confidentiality or similar obligations under this Agreement, the Confidentiality Agreements or any other agreement entered into in connection with the transactions contemplated by this Agreement, whether written or oral, between the
Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or affiliates, on the one hand, and any Investor or any of their respective officers, directors, agents, employees or investment advisers, on the
other hand, shall terminate. Without the prior written consent of any applicable Investor, the Company shall not (and shall cause each of its subsidiaries and affiliates to not) disclose the name of such Investor or any of its affiliates or advisers
(i)&nbsp;in any press release or marketing materials (including the Cleansing Release) or (ii)&nbsp;in any filing, announcement, release or otherwise, except with respect to this clause (ii)&nbsp;in a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> in which the Company files this Agreement or as otherwise required by federal securities law or to the extent such disclosure is required by law or Nasdaq regulations, in which case the Company shall provide the
applicable Investor with prior notice of and an opportunity to comment on such disclosure permitted hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Closing Conditions</U>. The obligation of the Company and each Investor (severally and
not jointly) to consummate the purchase and sale of the Purchased Shares pursuant to this Agreement is subject to the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) no applicable governmental authority shall have enacted, issued, promulgated, enforced or entered any injunction, judgment, order, law,
rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making the consummation of the transactions contemplated hereby illegal or otherwise enjoining, restraining or prohibiting consummation of
the transactions contemplated hereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) all deliveries in Section&nbsp;2 of this Agreement shall have been made by the Company and each
Investor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the
Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the representations and warranties set forth in Section&nbsp;3 and 4 above shall be true and correct in all respects (except for those
representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date hereof and on the Closing Date, with the same effect as if then made;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) each party shall have performed or complied with all obligations, covenants and agreements to be performed or complied with by it on
or prior to the Closing Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) no Material Adverse Change shall have occurred since the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Payment of Expenses</U>. All fees, costs and expenses incurred in connection with this Agreement and the transactions contemplated
hereby, shall be paid by the party incurring such expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Termination</U>. This Agreement shall terminate with respect to an
Investor and be void and of no further force and effect with respect to the Company and such Investor, and all rights and obligations of the party hereunder shall terminate without any further liability on the part of any party in respect thereof,
(i)&nbsp;upon the mutual written agreement of the Company and such Investor to terminate this Agreement or (ii)&nbsp;by either the Company or an Investor, solely as to itself, if the Closing has not occurred on or before the fourth business day
following the date hereof, provided, however, that the right to terminate this Agreement pursuant to this clause (ii)&nbsp;shall not be available to a party if such party&#146;s breach of a representation, warranty, covenant or agreement under this
Agreement has been the cause of the failure of the Closing to occur on or before such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company and the Investors (A)&nbsp;shall each execute and deliver, or shall cause to be executed and delivered, such documents and
other instruments and shall take, or shall cause to be taken, such further action as may be reasonably necessary to carry out the provisions of this Agreement and give effect to the transactions contemplated by this Agreement and (B)&nbsp;shall
refrain from taking any actions that could reasonably be expected to impair, delay or impede the Closing or the consummation of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither this Agreement nor any rights that may accrue to the parties hereunder (other than the Purchased Shares acquired hereunder, if
any) may be transferred or assigned with respect to an Investor without the prior written consent of the Company and such Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
All of the agreements, representations and warranties made by each party hereto in this Agreement shall survive the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For the
avoidance of doubt, each agreement between the Company and an Investor shall constitute a separate Agreement, and all obligations of an Investor hereunder are separate and several from the obligations of any other Investor. The decision of an
Investor to purchase the Purchased Shares pursuant to this Agreement has been made by such Investor independently of any other Investor. Each Investor shall be entitled to independently protect and enforce its rights, including without limitation
the rights arising out of this Agreement, and it shall not be necessary for any other Investor or investor to be joined as an additional party in any proceeding for such purpose. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) This Agreement may not be amended, modified, waived or terminated with respect to an
Investor except by an instrument in writing, signed by the Company and such Investor. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any
such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the
parties hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) This
Agreement and the Confidentiality Agreements constitute the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter
hereof. Except as expressly otherwise provided herein, this Agreement shall not confer any rights or remedies upon any person other than the parties hereto, and their respective successors and assigns, and the parties hereto acknowledge that such
persons so referenced are third party beneficiaries of this Agreement with right of enforcement for the purposes of, and to the extent of, the rights granted to them, if any, pursuant to the applicable provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) This Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and by different parties
in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed and delivered shall be construed together and shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) This Agreement shall be governed by and construed in accordance with the laws of the State of New York (regardless of the laws that might
otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including any action, suit, litigation, arbitration, mediation, claim, charge, complaint, inquiry, proceeding, hearing, audit, investigation or reviews by
or before any governmental entity related hereto), including matters of validity, construction, effect, performance and remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
Each party hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby, and waives right to any other jurisdiction to which it may be entitled by reason of present or future domicile, place of residence or any other reason and any objection which it may now or hereafter have to the laying of venue
of any such suit or proceeding in such courts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Any and all notices or other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the date of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the
signature pages attached hereto at or prior to 5:00 p.m. (New York City time) on a business day (provided no rejection notice is received), (b) the next business day after the date of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a business day or later than 5:30 p.m. (New York City time) on any business day, (c)&nbsp;the second business day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature
pages attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>SIGNATURE PAGES FOLLOW</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Investor has executed or caused this Agreement to be executed
by its duly authorized representative as of the date set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name of Investor: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State/Country of Formation or Domicile:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Purchased Shares: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate Purchase Amount: $ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal name of Investor in which
shares are to be registered: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax ID (if no Tax ID put N/A): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for purposes of notice: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; By checking this box, the Investor agrees to
wire the Aggregate Purchase Amount listed above to the account set forth below no later than June&nbsp;13, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Bank Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">SWIFT:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Account Holder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Account No.:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Routing Number:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has accepted this Agreement as of the date set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROKIDNEY CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for purposes of notice: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June&nbsp;11, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d814183dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class&nbsp;A Ordinary Shares and Concurrent Registered Direct
Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WINSTON-SALEM, N.C., June&nbsp;11, 2024 &#151; ProKidney Corp. (Nasdaq: PROK) (&#147;ProKidney&#148; or the &#147;Company&#148;), a leading
late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class&nbsp;A ordinary shares
at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15% of the Class&nbsp;A ordinary
shares sold in the underwritten public offering. All of the Class&nbsp;A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered
direct offering are each expected to close on or about June&nbsp;13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct
offering is not contingent on the closing of the underwritten public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProKidney&nbsp;currently intends to use the net proceeds from the
underwritten public offering and the concurrent registered direct offering for clinical trial costs and other research and development expenses, continued investment in its drug development platform, for its
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> and commercial activities, including its commercial manufacturing facility, and for other general corporate purposes, including for working capital, capital expenditures and general and
administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies, J.P. Morgan and Guggenheim Securities are acting as the joint book-running managers and PJT Partners is acting as a <FONT
STYLE="white-space:nowrap">co-manager</FONT> in the proposed underwritten public offering. PJT Partners is also acting as a financial advisor to the Company in connection with the offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement relating to the Class&nbsp;A ordinary shares was filed with the Securities and Exchange Commission and was declared effective
on November&nbsp;30, 2023 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275701).</FONT> A preliminary prospectus supplement and accompanying prospectus relating to the underwritten public offering has been filed with the SEC and are available
on the website of the SEC at www.sec.gov. A final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC&#146;s website at http://www.sec.gov or by contacting Jefferies LLC, Attn: Equity Syndicate Prospectus
Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) <FONT STYLE="white-space:nowrap">821-7388</FONT> or by email at Prospectus_Department@Jefferies.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717, telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-803-9204,</FONT></FONT></FONT> or by emailing at
<FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com;</FONT> or Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, 8<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York 10017
or by telephone at (212) <FONT STYLE="white-space:nowrap">518-9544,</FONT> or by email at GSEquityProspectusDelivery@guggenheimpartners.com. A preliminary prospectus supplement and accompanying prospectus relating to the registered direct offering
has been filed with the SEC and are available on the website of the SEC at www.sec.gov. A copy of the final prospectus supplement and accompanying prospectus relating to the registered direct offering can be obtained, when available, on the
SEC&#146;s website at http://www.sec.gov or by contacting the Company at ProKidney Corp., 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, North Carolina 27103, Attention: Bruce Culleton, M.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ProKidney Corp. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProKidney, a pioneer in the
treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney&#146;s lead product candidate, rilparencel (also known as
REACT<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-of-its-kind,</FONT></FONT></FONT> patented, proprietary autologous
cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance,
supporting its ongoing Phase 3 clinical program. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements within the meaning of federal securities laws with respect to ProKidney, including statements
that relate to the timing, size and completion of the public offering and the concurrent registered direct offering, the grant to the underwriters of the option to purchase additional shares in the underwritten public offering, the intended use of
proceeds from the proposed public offering and the concurrent registered direct offering and other information that is not historical information. Actual results or developments may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the underwritten public offering and the concurrent registered direct offering on the anticipated terms or at all, market
conditions and the satisfaction of customary closing conditions related to the offerings. More information about the risks and uncertainties faced by ProKidney is contained in the section captioned &#147;Risk Factors&#148; in the preliminary
prospectus supplement related to the public offering and the concurrent registered direct offering filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof,
and ProKidney disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: ProKidney Corp. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR INQUIRIES: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProKidney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ethan Holdaway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ethan.Holdaway@prokidney.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel Ferry </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel@lifesciadvisors.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>prok-20240611.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.6 -->
<!-- Creation date: 6/13/2024 1:34:48 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:prok="http://www.prokidney.com/20240611"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:us-types="http://fasb.org/us-types/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.prokidney.com/20240611"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prok-20240611_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prok-20240611_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>prok-20240611_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.6 -->
<!-- Creation date: 6/13/2024 1:34:48 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 2</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>prok-20240611_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.6 -->
<!-- Creation date: 6/13/2024 1:34:48 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="prok-20240611.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g814183g55h99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g814183g55h99.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "T E@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /=KW4++381-?7D%K$6VAYI BD]<9/?@_E5PA*;M!7]!.2CJ
MV)!J5C=6;7=O>V\ULN<S1RJR#'7Y@<<42A*+Y6K,%)-73([+6M*U*5HK#4[2
MZD4;BL,ZN0/7 -.=*I3UG%KU0E.,MF,DU_1H;LVDNKV,=R&VF)KA X/IC.<T
MU1J./,HNWH'/%.US1K(H* "@ H * "@ H ,B@ H * "@ H * "@ H \Y^-'_
M ")]I_U_)_Z+DKULI_C/T_5')B_@7J0^!/\ DD5]_N7/_H)I8W_?%\@H_P $
MYSX+_P#(R7__ %Z_^SK77FW\./J8X3XF8WB/_DK$_P#U_P ?\UK;#_[BO1D5
M/XY]#CI7S*/4.#^+FK:UH'@MM7T.X\F:VG0R_+G,9^7^96@#JUU:%O#:ZQD"
M VHN<_[.S=_*@#SCX*^/=4\7)JUMK4P>[MRDL7R[?W; _P B!^= &UK/B'57
M^+VA^'-/G"68M6NKT8SE<D*/;D#\Z .Y>ZMXWV//&K>A< T 8/CW5;G1O >L
M:G82!+FWMR\;XS@Y% '&ZYXPUFRTSX:RPW(5]:FMEO#M^^'$9;Z?>- 'J;R)
M$NZ1U0>K'%  TT2H':1 AZ,3Q0 1S12C,4B.!_=8&@!#<0@L#*@*_>&X<?6@
M ,\(C$AE0(>C;AC\Z ".>*4?NI4?_=8&@"2@#SGXT?\ (GVG_7\G_HN2O6RG
M^,_3]4<F+^!>I#X$_P"217W^Y<_^@FEC?]\7R"C_  3G/@O_ ,C)?_\ 7K_[
M.M=>;?PX^ICA/B9C>(_^2L3_ /7_ !_S6ML/_N*]&14_CGT..E?,H]0S/$FD
MIKOAK4M*D Q=6[Q GL2.#^!P: /'+7Q3*_[.7V<,?M^[^R O?<6V@?\ ?L_I
M0!N0:-%X-^,?AU+8!+74M):R.!@,\*@Y_)5H ?X&:7Q!XX\>>(+=U$@D&GV<
MK#*J$!&?ID*: .?NM#^'VCV4T/B[Q"=0\0L6,]Q#.[NC$G&U5Z8&."* +.EZ
MG=:I^S/JLEY<-</%%+"LC_>*JXQG\* *_BZ:*V\._!^XGD6.&*6T=W8X"J$B
M))]L4 :5K.GQD\6S.MVT?A;1W4>0K%7NY#G#,.H7CC_ZYP 8WB#6M$U?XG7^
ME>)=6;3_  [HR+#!9Q,R+,^!G.WL.?R'O0 _2]9\+^'_ (DZ ?!NK/+I^HR&
MTN[+>S*A; 1AN]\?E[T -L_"S>,/C/XOL+G4;JWTV!T>:."3:93@!1GL.IH
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+ !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140011541260560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 11,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROKIDNEY CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1586514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">2000 Frontis Plaza Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Winston-Salem<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">27103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">999-7019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Class&#160;A ordinary shares, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PROK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001850270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #/2,U8K!\7VX$$  #2$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V877/B-A2&_XJ&=GJU"9;Y3H$90I(NS6Y"0]I,V^F%L 5HUI9<2>:CO[Y'
M-K'IUAS3WF ;6Z\?Z1R]1_)PI_07L^'<DGT<23-J;*Q-;II-$VQXS,RU2KB$
M.RNE8V;A4J^;)M&<A5FC.&KZGM=MQDS(QGB8_3?7XZ%*;20DGVMBTCAF^G#+
M([4;-6CC_8\7L=Y8]T=S/$S8FB^X_3F9:[AJ%BJAB+DT0DFB^6K4F-";6[_K
M&F1/_"+XSIR<$]>5I5)?W,4L'#4\1\0C'E@GP>"PY5,>14X)./X\BC:*=[J&
MI^?OZ@]9YZ$S2V;X5$5O(K2;4:/?("%?L32R+VKWD1\[U'%Z@8I,]DMV^;-M
MKT&"U%@5'QL#02QD?F3[XT"<-.BTSC3PCPW\C#M_449YQRP;#[7:$>V>!C5W
MDG4U:PUP0KJH+*R&NP+:V?&="E(89$N8#,F]M,(>R$SFT891&S8MO,0]V@R.
M@K>YH']&\,=47A-*/Q#?\]O_;-X$M@+0+P#]3*]U1F^JMER3WR=+8S6$\(\J
MHERA7:W@\OK&)"S@HP8DKN%ZRQOC[[ZA7>][A*]5\+4P]7( 7P\)KX+#F_>O
M'A&(=@'1O@QBSK50+I A@72HY,&5BO#5Q:]3H'50P6-.O?"U<!$$QB<65X+A
M.O.7Y\?9W=/]KV3Z_#*_1LBZ!5GW$K*9#)1.E,[RG2PL#!N9JE1:?8!C6(E:
M(SQ Z'H%7>\2N@<1<?*4QDNNJT!P#<^C5VVOT_40GG[!T[^$YY7MR2R$5!,K
M$>1#=IX.5QSTKVBGW^U0+,T&!=[@$KQ)&,(4-\7Q$SQ&:!4;+@=%S2,/6H&J
M(?.(_<7(;;0-L;2C7FFYWO]F]2L=%]=;I )RUN]@8:8G!8'^%[JINWC6Y%7M
MJJL!KO8F)-0P>;5@$8\QOK(>4-3.O^;+)RP SK7:"AE4SM<:R:<I1E96 HI[
M^5=D<V4LB\AO(CGK(S6"?H]Z+0RMK \4M_4LBA-8MIU'P05:K2X&4E8#BMOX
M)Q7 F,PW2F*V5B,R& RN>A[%;):658#B;OVFA;5<PL#$<2J/IF8JJ7"A%8L,
MQY!*ZZ>X;R]4) )AA5R3SY#=6K"HD@=7J>4IK9_B3CW7/!L>#M,K7^MP&<*J
M['FU.A,_7*^6K'1]BOOTO\AFQJ1 5@N(R]8!^J77^S7>S(-4N\E'_25Y%3:J
MG'PU(M.(&9.O6"=$Z5!(V$ 1LV'@,Q_(M]XU5"M*$J;)ED4I)PET/;N+=:$L
M"#YNX:^:A2X5%X=XJ2H3L4; +=TPDI.M .[3Q6#>[X,-DVM^=BU9(_0T6=Q-
M?L*82M/W+S+]^YCKM1NE'T#!;EQ2)DP>*MEP0:M3-&ZEY_NX9;^3[0E$$+;1
MV6(MWR!48N%JM5.B+ $^[MX3F*AA-ED?(K:N1,$%:E%*[_<OV@), 49#69J!
M:>S)(Z\.&R[EIF"_X_F]RE58\V2'[KYV?&8N6PR)^ K4O.L>]%CG'Q#R"ZN2
M;-.^5-:J.#O=< :>YAZ ^RNE[/N%^PY0?,89_PU02P,$%     @ STC-6)^@
M&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8
MMD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2
M_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQD
MB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G
M8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E
M#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M
M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@
ML-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-C
MT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/C
MO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N
M5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J
M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ STC-6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " #/2,U8R="_K.\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #/2,U8F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( ,](S5BL'Q?;@00  -(1   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #/2,U8GZ ;\+$"  #B#
M#0              @ '%#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,](
MS5B7BKL<P    !,"   +              "  :$/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( ,](S5@<.&7J/P$  #P"   /              "  8H0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #/2,U8)!Z;HJT   #X 0  &@
M            @ 'V$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #/2,U899!YDAD!  #/ P  $P              @ ';$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   E%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d814183d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d814183d8k.htm">d814183d8k.htm</File>
    <File>prok-20240611.xsd</File>
    <File>prok-20240611_lab.xml</File>
    <File>prok-20240611_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d814183d8k.htm": {
   "nsprefix": "prok",
   "nsuri": "http://www.prokidney.com/20240611",
   "dts": {
    "inline": {
     "local": [
      "d814183d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "prok-20240611.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "prok-20240611_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prok-20240611_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-06-11_to_2024-06-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d814183d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-06-11_to_2024-06-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d814183d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "terseLabel": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "terseLabel": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.prokidney.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-24-160339-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-160339-xbrl.zip
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M; P916L9&QUNF['=:48V2</.4K.+.>"Y'/%&1KF0DT&M_WJ2:X&6Z;L_N1W
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MEX+E7+6!O\"H&-R,NV<$NU/<&$,P'QZRWK;P:!4Q^\ 51[14F%H%GS)8,MP
MF-I T>'FR@L.LPQ7$WX@'10L#BXZ;Q1:9?EF+!SAML8 [0"2  3P494#0,#J
MZ+*Z2*>XIW"5A&%E:68&R6(6!BZ9L2).G+B*&8U36VF&>2;>\U7AD0$U;VM2
M??@?&&K19"S$0:LV64TVAU=5EH#37Z%33# G2C ^Y</O6 4&+R?4FK[463%E
ML!.5U]$:,*> H4'Q%OT%MPRKC$4K$]F%H="08MM+Z@U456G$S#@>8GG 2!FM
MRASNA'\YR3!P:(AHU8$QBQ(L,63IJ[32:P.+B&) 5"F5?Q7[M9@,3)F7>>0D
MZ]R7V^$8VH3H%C2C*DU25:*$PA1^SKOY"M[.G(<NA=CAA@XDPN&?""ACJQB1
M1\UD$@"/S,ZGSZ.JUF!\DL@75,LJ!<Q(> L]E4'B?C 4WQ6*[],= ?3J(6.
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M9%:0PUBB&@VM-HY_?]"8#>G(7BK\+B>L, PDJK-57:A;!D9[BM:=32Y$K<Q
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M6?1@(^8WHQB8*+]?/$PE_I9U%\GJ0>113,2S(1N39WE)C")3YLH2%@PNGJ!
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M=\;DW'F@ 6>G@2V3[,AT(D8>]^  .IE0#>LSURZ"TN-?8/C@L4A8A2S"&@'
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M7@\VXM ["I\WM&K"P@)2"$9:LV9/;0);Y*/K1@RIG@&WUYMRPYB=ME^Y(ZT
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M;WUXOQQU"V\7K2$<!DS[5 '2*[ADA2E! ?W7Y4=%I%R5[CH6K@;*9+4;ZC#
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M-@YD'L,7/D[]RY<VF?&&NK#%P6H6&)_050>Q409W&;0;+,+$>'"QL9EZRHI
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M ^>Z6\053//H^-GC(\;S2E,(*L7Z\87;:=K$_N_+'W5[Z8=][M7\('(\F80
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M,K["]+YTN"6))PA.CPX%]6;F%-(428NH(;9C VK%E$R2E4]4AZU!RB(C7\N
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M7E9Z<DM)?%8>7ZR];NYV=0U+:[@'.(NSZ$99U1[M%.3!6=_*=V0<R %5!&-
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M1$C7LCH$[HKT-T'UB+,4?7ZQ_[9RP<5NQ,'3%E'I8546V=0"TPQU$0]ZY2E
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MZQEWK'14LJZ"8<7:5'CCOYU\%Q\='<6"TO8^3\_=V(I/6A_/E<K9XL\ZDH0
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M\ZH5<//\<@5)B4[8B2>Q.77N27V/UM/J G_#K4W,U!X<:ORE1HU_3K.1KI[
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MB/HV" =\LIH',B5@DRK;2(RBUYN-=V@2_'3-D27#%=;J+<3*#_!VHFUA)-I
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M#\DED2&9/%(:13K$"TL3P#22V1+.0]?YG,*_H9)H]3D)8? '=>1G=CM5AP7
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MU -T<TW.\>NLCA<$1:>I&N22W5 (BK+B?DT*U^3K%3S68+2CR8@FD=V;:$[
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M@S$,4K0_?BZA1O%4X4O6Y-R9A=8KH9:160&FF.31YD0M9H"RUT=P-4?P(9Y
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M]<O1"#263FP+QIMN_,#'+TH&()67F H267;X%.^DGMK!O.9UJ9P=/*K"H&9
M640E@-H4QF %F:C>7))&?@A=A=WUI[&.A]TJ12^"OTOP(<Y5BC0JLW7J+(!\
M2_#?*5RK]>5C>4Z49,MLSZFMYOP.-NCK#+Y'N!WSJP '7R+>^)7+'2/84QOZ
MN0RI3=3@M'&8"U1E8-CN:*5#<T]<"%EJJKTT0T_-8R>8!UY!F+B10=XA%Z9_
M=N"L##,$B+AH447 F-!MR5%4_B'2;".11K:X=9SPN78%-$F^I1PMD"2Q)M/
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MS::?PQ8;X#XOC+A4_5WQ\\'&X;O/&X<?-[JO7@.JJO'6Q^H1[='\X?CD_0<
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MZP@0P("!3A(5Y-@&O2Q!C ^B+ =Q -?:K:L<Y,((M*. )WX"0^MN5%^M;5M
MBWX4 ^E('W0>0DMBJ(P"8E;QPK_^T7W^Z@U,L=^E*'O$><9'=MX\$[V):,C'
M1A.'>I3*9.*_4R2A,M3SIP2%&K><B2L5%";*(_CS(,AQ:KJOM[<[,,]"0K^A
M"MNM>N/U-[P^X"5@=WP6J,M2F,@"VB_2-.8Y6X4V0]4'6S7$R;X*ABHL8B6Z
MS_ EH^ 3&17#N).!^URZWU<&?G=$E&6%XAXR"2_5:3JWSS5FB;XRSP6.[,5V
MY]6KYYU7KY^7$.";^,K+-R#[8YEES.0'[98V891(,Q'94 *+X3M2I,!R-S(N
ME/B?S?7-S<VN2&%>Z0FFKDB1^)>=Y]UNY^7VMI!A&.&G!'SZS8MFZVEALD+"
M--FA?\(/-H:)!J7$] &^<PMO>#@8RDS=N_55)0/$<_45\7HU74AZNQ7H.$;\
MWZAXTA'UKT[M>/.[_N3B!AB,:(#!ICKC#S"(;@@>R/26W3MB; 6$^@HM(;KP
M.P"4(H6?PS*<!N,,IB2&]PPP>AHI)PC:K5 '!4(4! FP7A.>3S]2D' PNTV!
M= "M&6!QX,1<G,HQ#4M]35'<BT27XDZ2=$.,LW1#9H)QR>1NB==N];4)%+4L
M\0*@#=K'*8 ^2SE%KU<SOBZ<2$YTWH&A37^G^@<:R5 1@5%RH[(\&K!PLU0A
MA1UA8*[IVX#$+F)Z@%D.>9>&] 7$3A9&))_YF\RQ#Q[GH[P#_O+P Z-4 XW@
M8YA9"IW( ]XK1FEU[3\%N-;]*+"/90ID:Y&##HLU?TB8/VR,]1-^0-9AH(+0
M2#?V/5 IP+< <'>]W0)@JQL0%%;<E')]_H=F:9XW]0XQ#C"4LN.+@30DR>$*
MF(#E,<L<?&@D<Y1']>%,\4<US2__L$/\N(ZMYS$W/>NFY^U[VLZ5RO()"(*W
M8IXSM=)T;L%)G^4?<IBEN^Y;D/ZMN>Z5J$^B>"BZWX@&3=>>IHP0P8!R!7@&
M#@CL91"&R,"!\X]"MI%B=I+@7]F+XB@'Q0'Z,0KA8?45I"DB:@JD[=8,<81P
M!LP-M 8=G\,O?)7ZP(>=6600XTPJBO HF2799EM49DI]51;[#'M]">-;8;RU
MH#!F2\5S&0BXLLB'8 *@2 ?#4,:Q $L?%"G:2"6DA0Q\Q6098EU\<DJ K-#2
M;+ ]K5I+$PP(,W'O)F ]N[\-X0]D+EC_XX0Y@0Q_"]Y+>Q^?_ZA&/92P=1)0
M_/<C,V+;!T1Y5H!:F!HID0<<"ST13X+8[Q<QC#Z540CV>0@VT8T"(I'54F 9
M-,N)&-1NSF)VQJ41JWVRE3R-A!J_W>HI)"1&.\39&9&I3.-G.# 9P+2&,@'K
M8@ZG82@UO6^<5OC V&FPVY\8M79A(N?W/F'\I-%Y,T[4$5XHYQ83]0E(H<!.
MNV6%K@W<=#M-*?QG?YMK_"CB?[MB^_D+\?KY:[$)XD_ C9^:-U[M[+P4>Y_V
MQ^/Q^IB_Z"#6/1FO@[;;V_BT?YMY^03$OU-F5(12?!/OT+7.AN+7"-LOI_);
M<VZ_B:.B)R/X]WVA3)*I"?SY00-;_H+_^29.T'8#-O\F?H;1T>U3G83 PM_$
M%;"O3)'EK;;">-71R:^ :)LPHF@\BO:4M4;=OE:CJ0G 2YY:Z9%$V97Q6$XR
MU $;*4[GATMQ=?)_,)W;*ZY=2FCM_N,U_:^1Z+"3='A\=GU\^4=36C^,+MZ?
M#C_.U[KM5FDY@4K1R+#%B.3^@<FC(&8W[2#+=!"Q9+\E/..<G#(F@>+_8&#4
MG8$=T!^2]92X<#&+\D7R2[#= "^/Y 2T6,>9@:1A8>917X(*RL$:C<GJM%IJ
M9HR)@Q96+XXCT/(]59JCK!T[GDJDONX,X24Z60/W#HV%7JQ<-&]UI, "=?H8
MW'$O% .N8&;' UKR)N)Y 9J08*?:+976LACJ.*PL U"QM>@5F:NWF*J/[OQ>
MUSQ>ZQ%F%*5 CS$1/?*.2]_8^8Y--S@K>E]PS-9_K!ZL^\>[4_)V:7S_)7U(
M+\K6)RN["JV5T;D9@78_7$0@0W,=WHJ"=8'-9B#295X OW3@=6 SZ*'=(H I
MZLP&U<O.#'+=F*5%87$+1A/TS[$N@T$/G2D;U 4-B6:_L7]E3%6JQ\B2&GWA
MH,A5O8]U<5 ;'X6_C(M> ^<C:2KTS/-,VVO\J@U"(BWH8\<J9^+0UL?< O,,
M&-;EI*ZCGEYZK3^:U^JBJ<V0=>:2/YF-:&/H%WY6P=$P,L!&V@!;Z#Y(4_1,
M\%$.F/HOW'CA;N=4<N"X#TXO"&,7VUL&1AX*L>T%A!C*FXC$"AM[:%%))XW]
M\%H]Z\C"$MYE0,V5KR"]<U,HET4RB,HED!X*I.<+"*3K1W$H&O!QECJE&&J-
M@Y+W6I=>ZXT &72@^GTT-0L_6$?QIYK!O83E0V'Y8D%A.<<CI,SW/!>T=&TK
MT88NJ[N-@JZOC.&2$W+.HJ2#OC4#MA%:[CA+D3U+&VYEF$.S@,N>&LJX[XQC
ME\K#T"D55*0FTL8Y2QQL+BL>ZFXC7G944.;0IETZHA=QYH2RQ0GE=]%OA4&!
MP,_RV1W7 [8N= "V)Y@$HZ7=^7"F>;F@3./D)V&)RFTZ/O 47/509XV%[PW+
ML"3_3C:K#-DQ\!9[C=!95"$4D2RACR@@@-<+F_H*<Q8Q#P,OP6#*PB5,0RX5
MP4,Q_6K!,7VI4*)EMT8VF\XW2,&"4X'6\G4E#T;]IXBL+(^Y&(<A?4]KB&,"
MADA2805RCX!X4B,!?F:Z?&,)UX?"=6?!X4HB&#ZWPI*<>M85@#+26.T)4I/^
M<!6+8VU $&*:ELR<NHTP'I8YX0YEC-LM,# "DJ78H;I!V9QHK..92NBRT R]
M@D=HO+*EEG!\*!Q?+R@<+U6FXX)#3'=(3M*M0S8H1V!=XC.871%55:%URFS%
MF[)H4PG+3X(\7\+T2!!AP3&9!EQ[S-%?GZ)&64=I;\^PL FL1S9"5AKZ52C9
M9IHXFFPS+\G=H6$8XYCN4XE'/I<^6ZG)-DV/.X81S3.EERG8OS8[=S<7E)^/
M2I-[;DG4@_W6BIE1;^51CMF2^[FENA?;>N#L02[J4A\]%,"+FE,,ACJJHGA^
MF;-?$8Z^*DAZ%K<##?A-:C91R08=X(.,V8#JTFW):;O5E^14>H$5+L[F0CK)
M0*;[#LO<)64QN4[;OE>D0Q67H?5 %R:W-,N\3K3S,DJT^W=!_S:*^>M%0'.+
M6)>)]/NC?A$3@M>-4M-F10M<!9]QI PXEW@A 1.MK+$HJU:7V'@H-A8QDW>F
M<15-Q$G@AB@#7>T@0K]GJ&\_9V(!DQ:@@H/9E?3M%CR4%;TL,%&/2H*$74RW
MS*@\(M 6-=-7AB8D5AB4Z.K45K&BJT7FHY>6JXQ.P \K1Y!0N+*$[#DP/M'V
MPY6,<@)W &>AZF&= SEB6#@7H'<5@@CL&SW"1[!VGH,?&1<)TJ*4*$MU%G'7
M!M<EY3;D#(2D1H/3!IVQ$VI+_ROX5D1&V13ON)4HE56 X,=(")%>C\\0.;S
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M6$#4![&,ROU;*)?:DUZL&>OBBYS!3O"2#ID6<RA-^3TO_@M>B2++!-[B'6?
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M[.'ZJSLNU);^7T+%+IK_1QVUYW]02P,$%     @ STC-6+L6G ZZ!   Z"T
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M2<Z#O:3<Z +SUO+FBODP[^#JDG\!4$L! A0#%     @ STC-6!E=N455$P
M7WP   X              ( !     &0X,30Q.#-D.&LN:'1M4$L! A0#%
M  @ STC-6#=[P&!(+@  <M,  !$              ( !@1,  &0X,30Q.#-D
M97@Q,#$N:'1M4$L! A0#%     @ STC-6%7!%-9.O   N=,# !
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M-C$Q7VQA8BYX;6Q02P$"% ,4    " #/2,U8NQ:<#KH$  #H+0  %0
M        @ $Q+0$ <')O:RTR,#(T,#8Q,5]P<F4N>&UL4$L%!@     (  @
*^P$  !XR 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>d814183d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prok-20240611.xsd" xlink:type="simple"/>
    <context id="duration_2024-06-11_to_2024-06-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="duration_2024-06-11_to_2024-06-11"
      id="Hidden_dei_AmendmentFlag_duration_2024-06-11_to_2024-06-11">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-06-11_to_2024-06-11"
      id="Hidden_dei_EntityCentralIndexKey_duration_2024-06-11_to_2024-06-11">0001850270</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_0">2024-06-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_2">PROKIDNEY CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_3">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_4">001-40560</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_5">98-1586514</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_6">2000 Frontis Plaza Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_7">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_8">Winston-Salem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_9">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_10">27103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_11">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_12">999-7019</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_25">Class&#160;A ordinary shares, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_26">PROK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_27">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_16">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-06-11_to_2024-06-11" id="Fact_18">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
